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ii. Index of Abbreviations
bp base pairs  
cDNA complementary DNA
Cys cysteine residue
c-fw common forward
ddH2O double distilled water
DMSO dimethyl sulfoxide
DNA desoxy ribonucleic acid
dNTP desoxy ribonucleotide
DTT dithiothreitol
dsDNA doublestrand DNA
EDTA ethylenediaminetetraacetic acid
ER endoplasmic reticulum
F factor
FBS fetal bovine serum
fw forward
GAPDH glyceraldehyd-3-phosphate dehydrogenase
GGCX gamma glutamyl carboxylase
Gla gamma carboxyglutamate/ ?-carboxyglutamic acid
Glu glutamate residue/ glutamic acid
kb kilo bases
kDa kilo Dalton
KH2 vitamin K hydroquinone
KO vitamin K epoxide
MCS multiple cloning site
MM Mastermix
nt nucleotide
OD optical density
PCR polymerase chain reaction
PDI protein disulfide isomerase
RDA recommended daily allowance
rev reverse
RLU relative luminescence unit
Diploma Thesis
7
RNA ribonucleic acid
RNAP RNA polymerase
RT reverse transcriptase/ room temperature
rpm rounds per minute
siRNA short interfering ribonucleic acid
SNP single nucleotide polymorphism
TBE Tris Boric Acid EDTA
TFBS transcription factor binding site
TE Tris EDTA
TF transcription factor
TM transmembrane
TSS transcription start site
UTR untranslated region
VK vitamin K
VKCFD combined deficiency of vitamin K-dependent clotting factors
VKD vitamin K dependent
VKOR vitamin K epoxide reductase
VKORC1 vitamin K epoxide reductase complex subunit 1
WR warfarin resistance
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I. ABSTRACT
Vitamin K epoxide reductase complex subunit 1 (VKORC1) recycles 
vitamin K epoxide to reduced vitamin K in the process of the components 
of the vitamin K cycle. Reduced vitamin K is used as a co-????????????????-
carboxylation of glutamic acid residues in vitamin K-dependent proteins. 
These proteins are only active following gamma-carboxylation. VKORC1 is 
the rate-limiting factor of vitamin K recycling and thus of gamma-
carboxylation.
Several polymorphisms in the VKORC1 gene have been identified and 
proposed to have an influence on the expression of the gene. One of 
these genetic variants is the promoter polymorphism -1639G>A. The G 
allele is said to be associated with a significantly higher promoter activity 
and higher expression of mRNA. Additionally, the A allele in homozygous 
form is associated with increased warfarin-sensitivity.
Since there have also been reports that the SNP -1639G>A does not have 
an influence on the expression of the VKORC1 gene, it was the objective 
of this study to conduct experiments to re-evaluate the influence of the 
promoter variation on the expression of the VKOR gene.
Two VKORC1 promoter constructs that were available in the laboratory, 
pGL3-G and pGL3-A, were used for the experiments. pGL3-G contained 
the G nucleotide at the position -1639, pGL3-A contained the A nucleotide. 
The constructs were transfected into HepG2 cells and promoter activity 
was measured in a Dual Luciferase Reporter Assay.
Two different transfection methods were evaluated and compared. While 
the commonly used reagent Lipofectamine produced rather variable and 
unreliable results the newly developed Metafectene PRO yielded more 
reproducible results and higher values in the Luciferase Assay.
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The Luciferase Assay with cells transfected with Metafectene PRO
indicated only a minor difference in the promoter activity between the two 
variants, with G giving slightly higher values. 
In conclusion, expression of the reporter gene was not significantly 
influenced by the G or the A version of the promoter in HepG2 cells. 
However, there is still the possibility that the influence of the SNP -
1639G>A is tissue-specific. 
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II. ZUSAMMENFASSUNG
Vitamin K Epoxid Reduktase Komplex Untereinheit 1 (VKORC1) 
regeneriert im Vitamin K Zyklus Vitamin K Epoxid zu reduziertem Vitamin 
K. Die reduzierte Form von Vitamin K wirkt als Kofaktor bei der Gamma-
Carboxylierung der Vitamin K abhängigen Proteine. Diese Proteine 
werden erst durch die Gamma-Carboxylierung in ihre aktive Form 
übergeführt. VKORC1 ist dabei der limitierende Faktor der 
Regenerationsrate von reduziertem Vitamin K und damit auch der 
Carboxylierung.
Einige Polymorphismen, die im VKORC1 Gen identifiziert wurden, dürften 
einen wesentlichen Einfluß auf die Expression des Gens ausüben. Zu den 
biologisch relevanten Varianten gehört unter anderem der 
Polymorphismus -1639G>A, der in der Promoterregion von VKORC1 
lokalisiert ist. Befindet sich das Nukleotid G an der Position -1639, so ist 
die Aktivität des Promoters angeblich signifikant höher, als in Anwesenheit 
des Nukleotids A an Position -1639. Aufgrund früherer Publikationen 
dürfte auch die Expression von mRNA in Gegenwart der G Variante 
erhöht sein.
Es wurde außerdem festgestellt, dass homozygote Träger des A Allels 
sensitiver auf das Antikoagulant Warfarin reagieren.
Andere Quellen berichten, dass der Polymorphismus -1639G>A keinen 
Einfluss auf die Expression des VKORC1 Gens ausübt. Es war daher das 
Ziel dieser Arbeit, den Einfluss des Polymorphismus in eigenständigen 
Experimenten zu untersuchen und zu bewerten.
Dazu wurden die beiden im Labor zur Verfügung stehenden Konstrukte 
pGL3-G und pGL3-A verwendet. pGL3-G trug die Promotervariante -
1639G, pGL3-A trug hingegen -1639A. Die Konstrukte wurden in HepG2 
Zellen transfiziert und die Promoteraktivität anschließend mittels eines 
Dual Luciferase Reporter Assays ermittelt.
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Es wurden zwei unterschiedliche Transfektionsmethoden evaluiert. Im 
Vergleich erzielte das häufig angewandte Reagenz Lipofectamine sehr 
variable und unzuverlässige Ergebnisse. Das neu entwickelte Metafectene 
PRO hingegen ergab im Luciferase Assay viel höhere Werte, zeigte 
jedoch auch eine relativ hohe Schwankungsbreite der Resultate, die 
allerdings nicht so hoch war wie mit Lipofectamine.
Die Ergebnisse, die im Luciferase Assay mit den mit Metafectene PRO 
transfizierten Zellen erzielt wurden, zeigten nur einen minimalen 
Unterschied zwischen den beiden Promotervarianten, wobei das Konstrukt 
pGL3-G geringfügig höhere Promoteraktivität aufwies. Die Expression des 
Reporter-Gens wurde nicht signifikant durch eine der beiden 
Promotervarianten beeinflusst. Es besteht allerdings immer noch die 
Möglichkeit, dass der Polymorphismus -1639G>A die Expression von 
VKORC1 gewebsabhängig reguliert. 
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III. INTRODUCTION
1. Vitamin K Epoxide Reductase Complex Subunit 1  
(VKORC1)
1.1. Identification of the VKORC1 Gene
VKOR stands for vitamin K epoxide reductase. This name was first 
introduced in 1970 by Bell et al.2 to describe an enzyme that was found to 
play an active part in the vitamin K cycle. It catalyzes the regeneration of 
vitamin K epoxide to vitamin K. 
Although the enzyme was identified in 1970, for a long time scientists were 
neither able to purify the VKOR protein nor to identify the gene expressing 
it.
In 2002 Fregin et al. found out that humans with a hereditary deficiency in 
several vitamin-K-dependent clotting factors have disorders in VKOR 
activity that can be mapped to human chromosome 16.13
Subsequently Rost et al. (2004) focused their research on chromosome 16 
in patients and rats with inherited defects of VKOR activity to localize the 
gene coding for VKOR. They found one particular gene that showed 
mutations in two families with defective vitamin-K-dependent clotting 
factors and in four families with hereditary warfarin resistance. Additionally 
they identified similar genes in fish, frogs and even mosquitoes.
The candidate gene encoded a small transmembrane protein that is found 
in the endoplasmatic reticulum. Since they were not sure if this protein 
was only a component of a larger complex, they named it vitamin K 
epoxide reductase complex subunit 1 or in short VKORC1.33
At the same time the research team of Darrel W. Stafford also succeeded 
in identifying the gene coding for VKOR by conducting siRNA knock-down 
experiments of 13 possible candidate genes encoding transmembrane 
proteins within the region 16p12-q21.20 They were the first group to identify 
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an unknown gene in mammalian cells through siRNA. Expression of the 
gene was subsequently confirmed in insect cells.
1.2. VKORC1 Gene
The gene VKORC1 is located on the short arm of the human chromosome 
16 in the region 16p11.2 and contains 5126 base pairs. It includes 3 exons 
with exon 1 spanning 173 bp, exon 2 encompassing 110 bp and exon 3 
spanning 209 bp which in total amounts to a coding region of 492 bp. 
There are two introns with intron 1 spanning 1125 bp and intron 2 
spanning 1969 bp. 
The gene also includes a 5’ untranslated region that stretches over 226 bp 
and a 3’ untranslated region that extends over 295 bp.
VKORC1 encodes a protein of the same name that is made up of 163 
amino acids and has a molecular mass of 18 kDa. It is a putative 
endoplasmic reticulum protein with three transmembrane domains.
Stafford and his team (2004) were able to identify VKORC1 not only in 
humans but also in rodents. In mice the gene is located on chromosome 
7F3, in rats on chromosome 1.
Interestingly, the human genome contains several DNA segments in other 
regions that are partially identical to VKORC1. In particular there is one 
segment on the X chromosome that is 93% identical and one on 
chromosome 1 that is 91% identical to the VKORC1 sequence. Yet, these
segments do not code for a protein similar to VKORC1 and are considered 
pseudogenes.34
Both Stafford's and Oldenburg's research teams found a homologous 
protein in the genome of the African malaria mosquito Anopheles gambiae 
but not in Drosophila melanogaster even though both species encode 
mostly the same conserved genes53 and despite D.melanogaster 
expressing a homolog of vitamin-K-dependent gamma-glutamyl 
carboxylase.21
In 2004 Hugh M. Robertson of the University of Illinois undertook a 
phylogenetic analysis and finally found a VKORC1 homolog in Drosophila 
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as well as in the sea urchin Strongylocentrotus purpuratus and the 
urochordate sea squirts Ciona intestinalis and Ciona savignyi.31
Homologs of the VKORC1 gene are also present in plants, protists, 
archea, and bacteria.26
Furthermore in the human genome a paralog of VKORC1 is present on 
chromosome 7 that was designated VKORC1-like1 (VKORC1L1) by Rost 
et al. (2004). This gene and protein is even more conserved in its 
sequence across the vertebrates than VKORC1 which differs by 8% in rats 
and mice, indicating that the VKORC1L1 sequence shows a very high 
degree of identity across species, above all in humans, rats and mice. Yet, 
the function of VKORC1L1 is still unclear.
According to Robertson's (2004) analysis the vertebrate lineage of 
VKORC1 is monophyletic and its rapid divergence could indicate that its 
function in vitamin K recycling is a derived one and VKORC1L1 might be 
the key to the original function.
The function of VKORC1 as it is known at present is that of a co-factor in 
the vitamin-K-cycle. Since the intake of vitamin K in the human diet is 
limited, the reduced form vitamin K epoxide that is generated during the 
gamma carboxylation reaction must be re-converted to vitamin K, so that it 
can be used again during gamma carboxylation. The enzyme VKORC1 is 
essential for the reduction of vitamin K.
1.3. VKORC1 Structure and Topology
The enzyme expressed by the VKORC1 gene is a 163-amino acid integral 
membrane protein located in the ER. Since the structure and function of 
proteins are interdependent, it is necessary to define the membrane 
topology of VKORC1 in order to fully understand its function and activity.
In 2005 the topology of the VKORC1 protein was experimentally 
elucidated by Tie et al.43 They used seven common computer programs to 
predict the topology and afterwards conducted in vitro experiments to 
confirm the results. Results of both analyses suggested that VKORC1 is a 
type III membrane protein with three transmembrane (TM) domains and 
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the orientation of Nexoplasmic/ Ccytoplasmic. Another example for a type 
III membrane protein would be cytochrome P450.
The N terminus lies in the lumen of the ER while the C terminus resides in 
the cytoplasm. The three TM domains span amino acids 10-29, 101-123, 
and 127-149. 
As depicted in Fig.1, only 12 amino acids are located in the lumen, while 
the majority lies in the cytoplasm in the form of a big loop that stretches 
from amino acid 31 to 100, and the C terminus which includes amino acids 
148 to 163. The remaining 66 amino acids make up the three TM domains 
which are all ?-helices in structure.
Considering the very short N terminal domain, it is highly unlikely that the 
active site residues are located in the lumen. There is a much higher 
probability of the active site is residing either in the cytoplasm or within the 
membrane. The latter hypothesis is supported by the fact that vitamin K is 
very hydrophobic.
In 2004 Goodstadt and Ponting16 proposed that a CXXC motif forms the 
active site of VKORC1, as this is the case in a number of other 
oxidoreductases, such as thioredoxin. If the CXXC motif is the active site 
Fig.1: Proposed membrane topology of VKORC1.43
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in VKOR, it would be located in the hydrophobic environment of the third 
TM domain and include Cys-132 and Cys-135, two of the four highly 
conserved cysteines in VKOR, the other two being Cys-43 and Cys-51. 
This proposal is consistent with the observation of Wajih et al. that the 
mutation of Cys-132 or Cys-135 to alanine abolishes VKOR activity.46
Since the discovery of the VKORC1 protein in 1970 2 numerous attempts 
to purify the molecule have failed. After having analyzed its structure and 
topology, Tie et al.43 suggested that these difficulties in purification were 
due to the localization of the active motif inside a TM segment. 
Solubilisation of the membrane prior to purification of the protein leads to 
an immediate loss of function. Thus the protein cannot be detected.
In 2006 Chu et al. of the research team of Darrel W. Stafford finally 
succeeded in purifying the VKORC1 protein.6
1.4. VKORC1 Function and Mechanism of Action
The function of VKORC1 is to regenerate vitamin K and very likely also 
vitamin K hydroquinone (KH2) from vitamin K 2,3–epoxide (KO). KH2 is an 
essential co-factor for the posttranslational carboxylation of glutamic acid 
????????? ?????? ??? ?-carboxy glutamic acid (Gla). Vitamin K-dependent 
proteins (VKD) are posttranslationally modified by this reaction and can 
only fulfil their biological functions after complete gamma-carboxylation. 
These biological functions are coagulation, signalling and bone 
metabolism.
C-132 and C-135 of the redox motif are essential for the conversion of 
vitamin K epoxide to vitamin K and of vitamin K to vitamin K 
hydroquinone.18
Since at present no three-dimensional structural data is available for 
VKORC1, only hypotheses on how its mechanism for the reduction of 
vitamin K epoxide by VKORC1 works have been published. The most 
probable hypothesis is that of Davis et al.11 which represents a 
modification of the Silverman mechanism37. It is proposed that to start the 
reaction mechanism, a reducing agent is necessary which provides 
electrons. This task is assumed to be the responsibility of thiol reagents, 
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presumably thioredoxin37, since it has been observed in some plants and 
bacteria that the VKORC1 active site is fused to thioredoxin-like (Trx) 
domains11, which, like VKORC1, contain CXXC motifs.
In contrast, Wajih et al. (2007) hypothesized that the reaction is driven by 
protein disulfide isomerase (PDI) together with the folding of proteins 
within the ER.47
Whichever agent might be responsible for the reduction, it is currently 
believed that this reduction of the CXXC redox center leads to the 
breakage of the disulfide bonds assumed to link the Cys residues in the 
active center. The disulfide is reduced to sulfhydryl.
The second important step is the reduction of vitamin K epoxide to the 
quinone form by protonation. A cysteine attack follows, leading to the loss 
of the proton and rearrangement followed by another protonation, attack 
by the second cysteine and finally loss of a water molecule by reductive 
elimination.
Davis et al.11 assumed the Cys residues to be CH3SH and the 
corresponding disulfide CH3SSCH3. The starting point hereby is CH3S
-
and the overall chemical reaction in short is:
HSCH3 + 
-SCH3 + H
+ à CH3SSCH3 + H2O.
Wang et al. (2005) observed that the VKOR protein is expressed 
ubiquitously in the human body, but primarily in the liver, kidney, heart, 
and skeletal muscle. They found expression to be higher in ventricular 
aneurysm tissue, adult heart after myocardial infarction and in fetal heart. 
This group hypothesized that VKOR might be involved in angiogenesis as 
well as tumor development and growth.50
1.5. Polymorphisms in the VKORC1 Gene
Polymorphisms, the short term for single nucleotide polymorphisms or, 
further abbreviated, SNPs, are point mutations that occur frequently in the 
population. Generally, genetic variants that occur with a frequency of at 
least 1% studying a given population, qualify as polymorphism. Since the 
identification of the VKORC1 gene, several SNPs have been identified and 
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the number is still increasing with every large study. Most of these SNPs 
are located in untranslated regions.
In 2005 Geisen et al. conducted a study among 200 blood donors from 
Western Germany and published a list of all SNPs that they found within 
the genomic sequence of VKORC1 including 1.8kb of the 5'- and 1.5kb of 
the 3'-flanking region (Table 1). They identified a total of 28 different 
SNPs. Three of these are located in the coding region, but they are silent 
and do not change the structure of the protein. The other 25 SNPs are 
located in non coding regions of the VKORC1 gene: seven in the 
promoter, 11 in introns and 5 in the 3'-UTR. In 14 SNPs the frequency of 
the minor allele is at least 1%, the other half of the polymorphisms was 
rare in the study cohort.15
N u cle o tid e  p o sitio n G e n e A lle le  fre q u e n cy
V K O R C 1 e x ch a n g e re g io n 1 (%) 2 (%)
-1795 T> C P rom oter 99,75 0,25
-1639 G > A P rom oter 58,5 41,5
-1453 G > A P rom oter 98,75 1,25
-1272 A > C P rom oter 99,75 0,25
-941 C > T P rom oter 99,5 0,5
-311 T> C P rom oter 99,75 0,25
-292 T> C P rom oter 99,5 0,5
36 G > A E x on 1 98,75 1,25
129 C > T E x on 1 99 1
181 C > T Intron 1 99,75 0,25
261 C > T Intron 1 99,75 0,25
305 A > G Intron 1 99,75 0,25
497 T> G Intron 1 69,75 30,25
503 G > A Intron 1 99,75 0,25
556 G > A Intron 1 99,75 0,25
698 C > T Intron 1 79,75 20,25
1173 C > T Intron 1 58,5 41,5
1542 G > C Intron 2 58,5 41,5
2255 C > T Intron 2 58,5 41,5
2714 A > G Intron 2 90,75 9,25
3462 C > T E x on 3 99,5 0,5
3647 G > A 3`R egion 99,75 0,25
3730 G > A 3`R egion 61,75 38,25
4182 G > A 3`R egion 99,75 0,25
4799 A > G 3`R egion 99 1
5155 C > T 3`R egion 98,75 1,25
5192 G > A 3`R egion 99,25 0,75
5198 G > A 3`R egion 99,75 0,25
N u cle o tid e
Table 1: Polymorphisms in the VKORC1 region detected in 200
blood donors from Germany. 15
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As mentioned above, new polymorphisms have been reported for 
VKORC1. Therefore, the list shown can by no means be considered 
complete. Up to now more than 40 different SNPs have been identified.
In 2004 Rost et al. identified two genetic variants in VKORC1 which are 
associated with phenotypic effects. 
The first phenotype is combined deficiency of vitamin K dependent 
coagulation factors type 2, or abbreviated VKCFD2. The second one is 
resistance to coumarin-type anticoagulant drugs or warfarin resistance 
(WR). Warfarin is an important oral anticoagulant used for the treatment of 
patients that have already suffered a thromboembolic event or who are at 
high risk of suffering such an event. Warfarin is the most popular and most 
commonly used coumarin-type anticoagulant drug worldwide.
It has been shown that response to warfarin treatment differs between 
individuals. One underlying cause are mutations in the VKORC1 gene. 
WR is primarily caused by the heterozygously inherited mutation 416 A>G 
in Intron 1.33 In contrast, VKCFD2 is the result of a homozygous point 
mutation, 292 C>T, in exon 3 in the patients studied,
Rieder et al. (2005) determined 5 specific SNPs that are clearly associated 
with variability in warfarin dose requirement in European Americans. 
These SNPs are: -4931T>C, -1639G>A, 1173C>T, 1542G>C, and 
2255C>T. They define 2 major haplotype groups designated A and B. 
Haplotype A carries the minor alleles and is associated with lower mRNA 
expression of VKORC1 and the need for a lower warfarin maintenance 
dose. Haplotype B carries the major alleles, shows higher mRNA 
expression and has higher warfarin dose requirement.29 Dose requirement 
means that patients require individually different doses of the warfarin to 
prevent thromboembolic events. 
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2. Vitamin K and the Vitamin K Cycle
2.1. Vitamin K
Vitamin K is a fat-soluble vitamin that occurs naturally in two main forms, 
designated vitamin K1 and K2. Both are derivatives of quinone which is a 
common constituent of biologically relevant molecules.
Vitamin K1 is also known as phylloquinone, which is synthesized by plants 
and is contained in green leafy vegetables like spinach and broccoli. 
Vitamin K2 is the collective name for a whole range of vitamin K forms 
found in foods like liver, milk, cheese, and fermented soy products, like 
Natto.55 They are menaquinones, designated MK-n, with n standing for the 
number of isoprenoid residues in the aliphatic side chain of the molecule. 
In food, the most important menaquinones are MK-7, MK-8 and MK-9. 
Schurgers et al. (2007) reported that MK-7 is the most effective form of 
vitamin K in the organism because it has a much longer half-life time in the 
circulation and a much higher cofactor activity in the vitamin K cycle than 
any other K vitamin.35
All forms of vitamin K are similar in structure and are collectively called 2-
methyl-1,4-naphthoquinones (Fig.2).
It has been observed that vitamin K1 is primarily taken up in the liver while 
vitamin K2 accumulates in the arteries and extra-hepatic locations.
39
Studies have shown that nutrition contributes mainly vitamin K1. This is 
because menaquinones are only contained in very small amounts of just a 
??????????? ????? ??? ???? ??????????????????????36 This is not enough to 
meet the RDA, according to the National Research Council 1989, of 
??????•d (per kg body weight per day).3
?????? ????? ????? ????? ???? ?????? ??????? ??? ???????????????? ????????????
Newer data report that MK-7 also contributes significantly to human 
vitamin K levels taken up by nutrients. Cheese is supposed to contain 50-
75mg of MK-7 per 100g.35
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The K in vitamin K stands for the Danish word “Koagulation”, referring to 
the process of blood clotting. The name was given by Henrik Dam in the 
1920’s after he found that chickens fed a fat-free diet developed a 
bleeding diathesis, but no known factor could be made responsible for 
this. Therefore he named the missing compound vitamin K and 
subsequently received, together with Edward Doisy, the nobel price in 
medicine or physiology for his discovery.55 Today it is clear that vitamin K 
is essential for the proper function of several blood coagulation factors. 
Lack of vitamin K can lead to internal haemorrhaging and bleeding 
disorders. It’s most important biological function is that of a cofactor in the 
?-carboxylation of proteins involved in the coagulation cascade and the 
for????????????????????????????-carboxylation is a step necessary for the 
activation of a number of important proteins including coagulation proteins, 
which are therefore referred to as “vitamin K-dependent”.
The carboxylation reaction is catalysed by the enzyme vitamin-K-
dependent carboxylase which uses oxygen and a reduced form of vitamin 
K to add a molecule of carbon dioxide to glutamic acid, thereby producing 
?-carboxyglutamic acid. This modification allows clotting factors to bind 
calcium ions, associate with membrane surfaces and clot blood.55 The 
second product that is generated during catalysis is vitamin K 2,3-epoxide 
which is recycled to reduced vitamin K by vitamin K epoxide reductase 
(VKOR).
The enzyme that is responsible for this modification is the vitamin K 
gamma glutamyl carboxylase (GGCX). It carboxylates the glutamic acid 
residue (Glu) of the protein, which is then referred to as the Gla amino 
acid (Gla). All reactions together are called the vitamin K cycle (Fig.2).40
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The vitamin K cycle can be divided into three main reactions: 
Carboxylation by GGCX
Regeneration of K from KO by VKORC1
Conversion of K to KH2 
Which enzyme this last reaction depends on is not yet clear. It might either 
be catalyzed by VKORC1 or by a seperate enzyme, i.e. the DT diaphorase 
(NAD(P)H dehydrogenase).40
???? ?-carboxylase requires not only reduced vitamin K as an obligate 
cofactor but also CO2 and O2.
41
The cycle starts with the binding of the carboxylase to its substrate, a VKD 
protein, which has a carboxylation recognition site within its mature protein 
sequence. This sequence is part of the propeptide which binds to GGCX 
and is defined by a ZFZXXXXA motif, with Z being an aliphatic 
hydrophobic residue like Ile, Val or Leu, F being phenylalanin, A being 
alanine and X standing for any amino acid.14
Fig.2: The Vitamin K cycle.26
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The carboxylase is a so-called processive protein, which means the 
enzyme binds tightly to its substrate and all carboxylations for this one 
substrate occur in one single binding event. During? ???? ????????? ???? ?-
proton on glutamic acid is removed and CO2????????????????????????????-
carbon. In the course of this process vitamin K hydroquinone binds the 
??????????????????? ????? ?????-carbon which leads to the conversion of 
KH2 to KO.
14
Dowd et al. (1995) proposed that this happens because KH2 acts as a 
strong base that substracts a proton from the glutamates in the VKD 
proteins to make carboxylation possible.12 For every molecule of Gla that 
is generated in the vitamin K cycle, one molecule of KO is produced.
The rate of carboxylation depends on the level of available vitamin K.40
This amount is limited since the dietary intake of vitamin K is usually 
relatively low. It is therefore the main responsibility of the vitamin K cycle 
to regenerate vitamin K for reuse to guarantee the efficiency of 
carboxylation which is absolutely necessary for keeping the VKD proteins 
and the whole coagulation system in order.
Since VKORC1 recycles vitamin K, VKORC1 is the rate-limiting factor of 
carboxylation. 
2.2. VKD Proteins
VKD proteins include proteins involved in haemostasis, coagulation factors 
VII, IX, X, prothrombin (procoagulant proteins), protein Z, protein S and 
protein C (anticoagulant proteins). These proteins contain 10-??? ?-
carboxyglutamic acid residues. The second group of VKD proteins 
comprises proteins of mineralized tissues. These include osteocalcin 
(bone Gla protein) and matrix Gla protein.  
Another VKD protein is Gas 6 which functions as a ligand for the Axl family 
of tyrosine kinase receptors19 and potentiates the growth of smooth muscle 
cells.14 Also counted among the VKD proteins are four putative 
transmembrane proteins, PRGP1 and PRGP2, named so for their proline 
rich protein characteristic14, TmG3, and TmG4.46
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Another group of known VKD proteins is that of conantokins which are 
conotoxins. These are small, paralyzing neuroactive peptides that are 
injected into prey by cone snail harpoons.14
?-glutamyl carboxylase itself can also be considered a VKD protein since 
its function depends on vitamin K as a cofactor.14
GGCX is, like VKORC1, an integral TM protein located in the rough ER.5 It 
is 758 amino acids long, has five TM domains and a molecular weight of 
about 94 kDa. Its NH2 terminus is located in the cytoplasm, the carboxy 
terminus lies inside the lumen.40 The human carboxylase gene is located 
on chromosome 2 at position 2p12. It is 13 kb long and contains 15 
exons.14 The carboxylase gene has been shown to be conserved not only 
in vertebrates like humans and zebrafish, but also in chordates such as 
Ciona intestinalis and a number of invertebrates like Drosophila 
melanogaster and Conus (cone snail).54
The biological function of the ?-glutamyl carboxylase is the activation of 
VKD proteins by carboxylation. Together with carboxylation the 
carboxylase confers metal binding properties on its substrates. These are 
very important for protein-membrane interaction.38
Through metal binding properties calcium ions are drawn to the plasma 
proteins and stimulate structural changes in which phospholipide binding 
sites are exposed of the hydrophobic residues on the surface of the Gla 
domain.14 The phosholipide binding sites for instance allow the blood 
coagulation factors to bind to the membranes of cells they react with.
Functional deficiencies of all vitamin K dependent coagulation factors or 
other VKD proteins leading to diseases, like hereditary combined VKD 
coagulation factor deficiency, can either be caused by mutations in the 
VKORC1 gene or, very rarely, by mutations in the ?-glutamyl carboxylase 
gene.10
Patients who show such deficiencies are usually administered vitamin K. If 
this treatment is not effective, it is very likely that the ?-carboxylase is the 
impaired component.5
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2.3. Vitamin K Antagonists
The substances that specifically inhibit VKORC1 function are the so-called 
VK antagonists which are derivatives of 4-hydroxycoumarin, or in short 
coumarin. These include acenocoumarol and warfarin, the latter being the 
most popular VK antagonist and anticoagulant.35
Warfarin (Fig.3) is a medication used for oral treatment and prevention of 
thromboembolic events because it “thins” blood. It is in fact the most 
widely used and prescribed anticoagulant worldwide and has been in use 
since 1955 when US-President Dwight Eisenhower received warfarin as 
medical treatment after a heart attack.
Its discovery dates back to the early 1940s. Before that time cows had 
been bleeding to death in the northern United States after eating mouldy 
sweet clover hay. In 1940 Karl Link discovered that the responsible fungal 
product could only be a vitamin K antagonist and named it warfarin, after 
the Wisconsin Alumni Research Foundation, to which he assigned the 
patent rights.33
Warfarin causes intense internal bleeding when administered in large 
doses and is therefore also used as a very effective rat poison. In small 
doses it can, however, prevent lethal blood clots that can form in the 
lungs, hearts and brains of susceptible people, and thus save lives.
It has been observed that some rats and mice develop resistance to 
warfarin and similar poisons, a condition that can also occur in humans. 
Resistance to warfarin in the human context does not mean that the 
person's system shows no reaction to the medication at all. However, 
Fig.3: Chemical Structure of 
Warfarin 53
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extraordinarily high doses of warfarin will be necessary to antagonize 
blood clotting.33
It is estimated that warfarin prevents twenty stroke events per induced 
bleeding episode. Still, warfarin is under-used since dosage control is 
rather complicated because patients respond quite differently to the 
treatment and there is always the risk of inducing bleeding.34
Warfarin acts as an antagonist to VKORC1 and thus to the carboxylation 
of VKD proteins. It is now believed that SNPs in VKORC1 have a high 
influence on the dose response to the medication. 
Rost et al. (2005) assume that the target for warfarin is the redox center in 
VKORC1 (Fig.4), to which warfarin binds and thereby prevents 
carboxylation and subsequently coagulation.32 Different SNPs might have 
different effects on this reaction.
Indeed, doses of warfarin causing adequate anticoagulation are correlated 
with SNPs in the genes for VKORC1 and cytochrome P450 2C9 
(CYP2C9).7 In 2004, Ansell et al. published guidelines suggesting initial 
warfarin dosing of 5 to 10mg per day for people receiving first treatment.1 
However, experience has shown that some patients need a much lower or 
much higher dose. Incorrect dosing can lead to bleeding in high
responders or to thrombosis in low responding individuals. Warfarin 
sensitive people need doses of around 1.5 mg/d. As has been shown, 
polymorphisms in VKORC1 have an effect on the formation of reduced 
vitamin K which in turn affects warfarin dose response and blood clotting.49
For instance D'Andrea et al. (2005) found that people carrying the T allele 
of the polymorphism 1173T>C in intron 1 require a lower dose of warfarin 
than those carrying the C allele. This indicates a lower activity of the 
VKORC1 1173 T allele to revert KO to KH2.
9
Montes et al. (2006) found that the A allele of the -1639G>A promoter 
variant is associated with a low dose requirement for the anticoagulant 
acenocoumarol.23
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Other polymorphisms result in a high dose requirement and some
mutations can also cause warfarin resistance such as the heterozygous 
missense mutation 416A>G discovered by Rost et al.33
3. Promoters and Promoter Variants
3.1. Promoters
Promoters are DNA regions located upstream of genes. They belong to 
the non-coding part of the DNA strand in the 5'-untranslated regions and 
contain certain elements, the so-called transcription factor binding sites 
(TBFS), transcription factors (TF) can bind to. Promoters are highly 
conserved motifs with a length of 6-12bp and represent regulatory 
sequence elements that are recognized by the TF.27
Every gene has its own promoter where transcription for this one particular 
gene is started and regulated. Transcription starts downstream of the 
promoter and proceeds in the direction 5'-3', resulting in a newly 
synthesized mRNA strand having the orientation 3'-5'.25 Promoters are 
always located on the sense strand of the DNA – which is transcribed; the 
antisense strand does not contain a promoter.
Promoters act as transcription start sites (TSS), which means that the 
process of transcription begins with the RNA polymerase (RNAP) binding 
to particular DNA segments within the promoter. The TSS is characterized 
by very short consensus sequences of 6-10bp. This short sequence 
principally opens the possibility of the RNAP to bind to similar sequences 
somewhere else in the gene. However, usually the RNAP locates the right 
binding site. What guarantees the specificity is still not quite clear.28
In prokaryotic genes the RNAP is able to initiate transcription by itself, 
?????? ???? ?????????? ????? ???? ?-factor is present. In eukaryotic genes the 
RNAP needs transcription factors that bind to their recognition sequences 
within the promoter and constitute the transcription-initiation-complex 
together with the polymerase. The TF are responsible for phosphorylation 
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and subsequent release of the RNAP which then starts the transcription 
process.25
Promoters of eukaryotic as well as of prokarytic genes contain 
characteristic consensus sequences that are essential for the correct 
binding of the RNAP to the DNA strand. In prokaryotic or bacterial 
promoters these sequences are the Pribnow- or TATA-Box or -10-region, 
because the nt at the starting point is designated +1, with the sequence 5'-
TATAAT-3' located 10bp upstream of the TSS and the -35-region located 
35bp upstream of +1 with the sequence 5'-TTGACA-3'. These elements 
do not need to have the exact same sequence as pictured here and need 
not be identical in every gene but have to be similar, for example the 
TATA-Box can also have the sequence 5'-TATGAT-3' and can still function 
as binding site.
Often a third element can be found that is called UP-element. The 
abbreviation UP results from the element’s location directly UPstream of 
the -35-region. It contains a number of AT basepairs which are recognized 
??? ???? ?-subunit of the RNAP that binds to this particular region of the 
promoter.
Eukaryotic promoters also contain the TATA-Box but this one is located at 
-25 base pairs upstream. Its sequence is 5'-TATAAAT-3' and is recognized 
and bound to by the RNAPII which catalyzes the synthesis of the mRNA 
strand in eukaryotes. The second important sequence is the CAAT-Box 
that is located at about position -70 and has the sequence 5'-CAAT-3'.51
Especially in eukaryotic cells the vast majority of genes is usually silent 
and is not transcribed until a certain gene product is needed. The 
mechanism of turning off genes is called silencing. The process is carried 
out by proteins called silencers. The counter mechanism is called 
enhancing and is carried out by so-called enhancers. A process 
somewhere in the middle between these two is the up- and down-
regulation of the gene expression which is influenced by the TFs. All three 
groups of proteins need cis-acting regulatory elements or sequences, that 
lie promoter-proximal, to bind to. The promoter-proximal elements in 
eukaryotes are the same as the UP-elements in prokaryotes. They are 
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found within about 100-200bp upstream of +1. The CAAT-Box is one of 
these elements, as well as a GC-rich segment that is often found a little 
further upstream.17
3.2. The Promoter Variant -1639G>A in the VKORC1 
Gene
Promoter mutations are point mutations within the promoter of a gene. 
They can lead to an increased or decreased expression of a particular 
gene. These point mutations can change binding sites for proteins. If a 
binding site for a protein is changed that normally activates transcription, 
gene expression decreases.25
In 2005, Yuan et al. conducted a study to determine the effect of the 
-1639G>A promoter polymorphism in VKORC1 on warfarin sensitivity and 
promoter activity.52 The group found that patients carrying the -1639A 
allele in homozygous form (A/A) were warfarin sensitive (<1.5mg/d) and 
had low dose requirements. The authors hypothesized that this was 
because the -1639G>A SNP is located in an E-Box with the consensus 
sequence CA/GNNTG. E-Box sites are important elements for mediating 
cell and tissue type specific transcription, like in muscle, neuron, liver, and 
pancreas.52 In carriers of the -1639A allele the consensus sequence of the 
E-Box is CANNTG, in carriers of the wild type allele -1639G the second 
base is changed and the sequence is converted to CGNNTG. Yuan et al. 
conducted a promoter assay in HepG2 cells which showed that the 
CGNNTG sequence increases the promoter activity by 44%.52
Another study by Bodin et al. (2005) could not confirm these results. 
Although they used the same cell line as Yuan et al. (2005), no difference 
in promoter activity between the -1639A and G alleles could be observed.4 
One possible explanation for this difference in results might be that Yuan 
et al. used lipofectamin for transfection whereas Bodin et al. used calcium 
phosphate. Also, the promoter sequence that was used for both studies 
differed by a few base pairs.
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A very recent study by Wang et al. (2008) again confirmed that the G 
allele increases promoter activity. These authors also tested mRNA 
expression in a reporter gene assay using HepG2 cells and found that the 
-1639A allele is associated with a 2-fold lower level of VKORC1 mRNA 
and therefore also reduced warfarin maintenance dose. But they also 
observed that the effect of the SNP is tissue-dependent, because they 
could not reproduce the results obtained in HepG2 cells in B lymphocytes
and heart tissue.48
4. Full-Length cDNA Constructs 
cDNA constructs comprise the sequences of the coding region from the 
CAP site to the poly A site. The template for the cDNA is the coding 
sequence of the mRNA.
The first step of constructing a full-length cDNA construct is the isolation of 
total RNA from cell material. Relatively high amounts of mRNA are 
????????? ???? ??????? ??? ??? ??? ??????22 The second step is synthesis of 
cDNA, a process that is accomplished by reverse transcriptase which is 
responsible for creating the complementary DNA strands to the single 
mRNA strands.
After synthesis the full-length cDNA is enriched by PCR amplification with 
sequence specific primers which should also add restriction sites to the 
sequence, which will later be necessary for cleavage with restriction 
enzymes.
Fig.4. Example for a full-length construct: pGL3 basic vector with 
mip2 gene insert60
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To generate a transferrable cDNA construct, cloning into a suitable vector 
is required. The vector has to have the capacity of taking up fragments of 
the length of the construct. For smaller inserts of a size up to a few kb, 
plasmid vectors are suitable. 
Both, vector and insert have to be digested with restriction enzymes to 
create matching ends. Restriction enzyme digestion also linearizes the 
vector and thus enables it to take up the insert DNA.
The insert is integrated into the vector during the process of ligation which 
is accomplished by an enzyme called ligase. The ligase joins the ends of 
the two DNA fragments, namely vector and insert, and produces the full-
length construct. 
Subsequently the construct can be transformed in bacterial cells. The full-
length constructs that have been obtained can now be, for instance, 
transfected into cells for further experiments, such as testing expression 
levels in certain cell lines.
5. Focus of this study
This diploma thesis focuses on the gene variant  -1639G>A in the 
promoter region of the VKORC1 gene.
In the first part of the diploma thesis the -1639G and -1639A variant were 
examined in a cell culture model to find out if they indeed influence the 
expression of the VKORC1 gene. As pointed out earlier, the current 
literature on this topic is controversial.
As it could not be excluded that the transfection methods contribute to or 
influence the results of the reporter gene assays and the interpretation of 
the effect of the promoter sequence on gene expression, different 
transfection methods should be evaluated.
In the second part of the thesis, a construct of the VKORC1 promoter and 
coding region was prepared and cloned. 
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IV. MATERIALS AND METHODS
1. Materials
1.1. Reagents
Agarose
Sigma Aldrich, Germany
AmpliTaq Gold Polymerase and 10x PCR Buffer
Roche, USA
Aqua bidestillata/ ddH2O
Mayrhofer Pharmazeutika, Austria
Bacteriological Agar
Sigma Aldrich, Germany
Big Dye® Terminator v3.1 Cycle Sequencing Kit, Big Dye® Terminator Mix, 
5x Sequencing Buffer
Applied Bioscience, UK
Criterion™ 5% Acrylamid Precast Gel
Bio-Rad Laboratories, USA
Dimethyl Sulfoxide (DMSO)
Sigma Aldrich, Germany
DMEM+GlutaMAX™-I 1x
Gibco, UK
Dual Luciferase® Reporter Assay System
Promega Corporation, USA
Ethidium bromide (10mg/ ml)
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Sigma Aldrich, Germany
FastRuler™ DNA Ladder, High Range
Fermentas International, Canada
Fetal Bovine Serum (FBS)
Gibco, UK
Gel Star
Invitrogen, USA
GeneRuler™ 100bp DNA Ladder
Fermentas International, Canada
Glycerol, 99.5% A.C.S. Reagent
Sigma Aldrich, Germany
LB Broth
Becton Dickinson, USA
Lipofectamine™ 2000 Reagent
Invitrogen, USA
Loading Buffer 5x
Elchrom Scientific AG, Switzerland
MgCl2 Solution 25mM
Roche, USA
Metafectene™ PRO
Biontex, Germany
Montage™ SEQ96 Sequencing Reaction Cleanup Kit
Millipore, USA
OPTI-MEM® I+GlutaMAX™-I1x
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Gibco, UK
pBR322 DNA-Msp I Digestions
New England Biolabs, USA
PBS
Gibco, UK
PfuUltra™ Hotstart DNA Polymerase, PfuUltra™ HF Reaction Buffer 10x
Stratagene, USA
QIAprep® Spin Miniprep Kit, EndoFree® Plasmid Maxi Kit
Qiagen Inc., USA
Rapid-Load™ PCR Loading Dye
OriGene Technologies, USA
Restriction Enzymes HindIII (10U/?l), XbaI (10U/?l), XhoI (10U/?l)
Fermentas International, Canada
SYBR® Green I nucleic acid gel stain 10 000x
Molecular Probes, Netherlands
???????????????????????????Ligation Buffer
Roche Diagnostics, Germany
5x TBE Buffer
Eppendorf, Germany
0.05% Trypsin-EDTA 1x
Gibco, UK
1.2. Cells and Cell Lines
HepG2, Hepatocellular Carcinoma Human
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ATCC®, HB-8065
Lot: 4004528
One Shot®TOP 10
Invitrogen, Carlsbad CA, USA
?????chemically competent cells
self-made by fellow student Harihara M.P.S.
1.3. Cloning Vectors and Constructs
pGL3 basic vector
Promega Corporation, Madison WI, USA
Description by the manufacturer:  
The pGL3-basic vector lacks eukaryotic promoter and enhancer 
sequences, allowing maximum flexibility in cloning putative regulatory 
sequences. Expression of luciferase activity in cells transfected with this 
plasmid depends on insertion and proper orientation of a functional 
promoter upstream from luc+.
Base pairs 4818
Promoter none
Enhancer none
Multiple cloning region 1 to 58
Luciferase gene (luc+) 88-1740
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Two constructs with the pGL3-basic vector containing an inserted 
promoter had previously been made by a fellow student. They were used 
for the experiments in this thesis. These two constructs are pGL3-A and 
pGL3-G, both containing one of the two variants of the promoter SNP -
1639G>A.
phRL-TK vector
Promega Coporation, Madison WI, USA
Base pairs 4045
HSV-TK promoter 7 to 759
Chimeric intron 826-962
T7 RNA polymerase promoter 
(-17 to +2)
1006-1024
T7 promoter transcription start site 1023
hRluc reporter gene 1034-1969
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2. Methods
2.1. Preparation of Plasmids from Glycerol Stocks
The plasmids containing the wildtype (-1639G) and variant (-1639A) 
promoter were kept frozen at -80°C in a glycerol stock. They were thawed 
and propagated to be used in my thesis experiments.
A small aliquot of each construct was plated out on LB agar plates 
?????????????????????? ???????????????????? ????? ?????????????????????? ???????
the resulting colonies were picked and inoculated in 2ml liquid LB media 
each and then incubated at 37°C on a shaker for 16 hours.
The plasmid DNA was isolated following the protocol of the QIAPrep Spin 
Miniprep Kit using a microcentrifuge. According to the manufacturer, the 
????????????????????????? ?????????????? ????????????????????????????? ???
sufficient for sequencing and restriction enzyme digestion. To obtain 
enough material for transfection experiments, Endofree Plasmid Maxiprep 
preparation was performed. 
For this procedure 100ml liquid cultures were inoculated also with colonies 
obtained from the glycerol stock.
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2.1.1. Miniprep Procedure
Following lysis of bacterial cells, selective adsorption of the plasmid DNA 
onto a silica membrane and subsequent washing, the DNA was eluted 
from the column during a centrifugation step using an Eppendorf 5415 D 
microcentrifuge.
The starting materials for the Miniprep were 2ml liquid cultures inoculated 
with the colonies prepared from the glycerol stock. After 16 hours of 
incubation 1.5ml of these bacterial cultures were transferred to Eppendorf 
tubes, centrifuged and the cell pellets washed with three different buffers 
contained in the Qiagen Kit. The resulting supernatants were applied to 
QIAprep spin columns which were centrifuged and washed followed by 
elution of the plasmid DNA. 
The eluted plasmid DNA was analyzed for right size and amount of DNA 
by gel electrophoresis on a 0.8% agarose gel. Electrophoresis was 
performed at 100V for 50min. A High Range DNA Marker was used to 
determine the size of the bands.
To make sure that not only the whole plasmid but also the inserted 
promoters were of the right length, they were cut out by restriction enzyme 
digestion with XhoI and HindIII in buffer R and ddH2O. Restriction was 
performed by incubation at 37°C for 2 hours. Both restriction enzymes 
???????????????????????????????????????
The resulting DNA fragments were also tested for right length on a 0.8% 
agarose gel.
2.1.2. Maxiprep Procedure
In the course of the Maxiprep plasmid DNA was isolated from 100ml liquid 
over night cultures using a Hettich Rotanta TRC centrifuge.
The cultures were transferred into 50ml Sarstedt tubes, centrifuged and 
the cell pellets washed three times. The resulting lysates were filtered and 
the plasmid DNA was thereby caught inside the filter membrane which 
was then washed to release all none DNA material. Plasmid DNA was 
eluted by application of elution buffer.
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The plasmid and the insert cut out of the plasmid with XhoI and HindIII 
were analyzed on a 0.8% agarose gel. Running conditions for the gels 
were 100V for 50min. 
2.1.3. Pooling of Plasmid DNA
The Maxi-Prep DNA samples were pooled and aliquoted into samples of 
???????
The OD of each pool was determined using a NanoDrop® ND-1000 
spectrophotometer. The concentrations of the samples were later required 
for transfection of the HepG2 cells.
2.1.4. Preparation of new Glycerol Stocks
One ml of fresh LB media was inoculated with bacterial colonies that were 
picked for the plasmid preparations. Following 16 hours incubation the 
cultures were mixed with glycerol at a ratio of 60:30. For each of the 
constructs about 1ml of glycerol stock was prepared. The glycerol stocks 
were stored at -80°C.
2.2. Sequencing 
2.2.1. Cycle Sequencing
The sequencing reaction was carried out using a Big Dye® Terminator v3.1 
Cycle Sequencing Kit.  
The sequencing PCR with four ddNTPs (ddATP, ddGTP, ddCTP, and 
ddTTP), was performed in a 96-??????????????????????????????????????????????
sample. This volume contained the Big Dye Sequencing Buffer and Ready 
Reaction Mix contained in the kit, 25ng of plasmid, 5pmol primer and 
deionized water. In every well only one primer was used. The following 6 
primers were applied:
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Designation Position Sequence 5'-3'
VKORC1 5’UTR3 fw 4225-4243 AGTGTAGATGGGGAGGATG
VKORC1 5’UTR4 rv 5025-5006 GGGAAATGAAGTCTCCACAG
VKORC1 5’UTR1 rv 4080-4961 CTTCCTCACTTCTTCCTTGC
VKORC1 5'UTRi fw 3514-3539 CCGCTCGAGTAGATGTGAGAAACAGCATCTGG
VKORC1 5'UTRi rv 5277-5260 CCCAAGCTTAAACCAGCCACGGAGCAG
VKORC1 5'UTR2 fw 3924-3938 CTGGGCGACAGAGT
Table 2. Primers used for Cycle Sequencing
The cycle sequencing reaction was performed on a PE 9700 Thermal 
Cycler. The temperature protocol was: 
Denaturation for 1' at 96°C followed by 25 cycles of 10'' at 96°C, 5'' at 
50°C and final elongation for 4' at 60°C. Finally the samples were cooled 
to 4°C. 
2.2.2. Purification
Before sequence analysis the samples were purified using a vacuum 
pump. They were therefore transferred to a SEQ96 plate and diluted with 
?????????????????????????????????????????????????????????????????????????????
This procedure was repeated once. 
2.2.3. Sequence Analysing
The instrument used for analyses of the sequences was an ABI PRISM®
3100 Genetic Analyser. The separation technique of these sequencing 
machines is capillary electrophoresis. The software program used to read 
the sequences was SeqScape®.
2.3. Cell Culture
The cell line used for the transfection experiments was a HepG2 cell line 
obtained from ATCC, which was derived from a 15 year old male 
Caucasian with a hepatocellular carcinoma.
The product was received in an ampule containing 1ml of 3.8 x 106 cells/ 
ml and treated according to the company recommendations. The cells 
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were thawed at 37°C for approximately 2 minutes. Under sterile conditions 
????????????????????????????????????????????????????????????????????????????
5ml of FBS and immediately centrifuged at 1200rpm for 5min. This 
procedure was repeated, the resulting cell pellet resuspended in 8ml of 
DMEM and transferred into a 75cm³ flask containing 8ml of DMEM plus 
geneticin. The culture was then incubated at 37°C. Media was changed 
twice a week.
2.3.1. Passaging
Depending on their confluence the cells were split (or passaged).
The culture medium was discarded and the cells washed once with 5ml of 
PBS. The cell layer was rinsed with 4ml of 0.25% trypsin/ 0.53mM EDTA 
solution. Then, 5ml of trypsin-EDTA was added and the cells were 
incubated for 15 minutes to disperse the adherent cell layer.  Five ml of 
complete growth medium were added and the flask tilted a few times to 
release cells that still stuck to the bottom. The contents were transferred 
into a fresh 50ml Falcon tube and centrifuged at 1000rpm for 5min. The 
supernatant was discarded and the cell pellet resuspended in about 4ml of 
complete growth medium which was then distributed to two new 25cm2
flasks.  
2.4. Transfection of HepG2 Cells
2.4.1. Lipofectamine™ 2000 as Transfection Reagent
24 hours before transfection, the cultured cells were seeded into a 24-well 
plate with approximately 4 x 105 ??????????????????????????????????????????
medium without antibiotics each. The plate was incubated at 37°C.
For transfection 750ng of the pGL3 basic vector, the pGL3-A and the 
pGL3-G construct was used, of the phRL-TK vector 25ng were used. All 
samples were diluted in Eppendorf tubes with 50?l of Opti-MEM. After 
5min incubation at room temperature Lipofectamine (diluted with Opti-
MEM at a ratio of 1:25) was added to reach a total volume of 100?l. The 
samples were incubated for 20min at room temperature. They were then 
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added to the cells in the 24-well plate instead of the growth media. For 
each sample 4 transfections in 4 separate wells were conducted.
The plate was incubated for another 48hours at 37°C prior to the 
Luciferase Reporter Assay.
2.4.2. Metafectene™ Pro as Transfection Reagent
Metafectene™ Pro is a new reagent for efficiently transfecting moderately 
hard- or hard-to-transfect cell lines. It uses two new techniques that are 
called TOP (Toxicity Optimization Module) - and RMA (Repulsive 
Membrane Acidolysis) -Technology.
Transfection with Metafectene basically uses cationic lipids for intracellular 
gene transfer. These cationic lipids form a DNA-lipid-complex or lipoplex 
with the genetic material they are supposed to transport into the cell. The 
complex is then taken up by the target cell through endocytosis.
Afterwards the DNA resides in the cytoplasm in the form of lipoplex-
containing endosomes. By osmotic disruption the lipoplexes are released 
into the cytosol. The plasmid DNA must now reach the nucleus but since it 
cannot penetrate the nuclear membrane by itself, transfection can only 
take place during cell division when the nuclear membrane opens.
With RMA technology the acidic environment caused by the breakdown 
of the endosomes is used to weaken the membrane structure of the 
lipoplexes. Repulsive forces between the positively charged lipophilic parts 
of the lipids then lead to the easy disruption of the membranes. 
Consequently a very high amount of naked genetic material is released 
into the cytosol.
TOP technology decreases the toxic effects of transfection throughout 
the whole process. This is very important to maximize the success of 
transfection. Furthermore it helps to destabilize the lipoplexes.
For transfection with Metafectene, the cells were seeded into a 24-well 
plate with 4 x 105????????????????????? ????????????????????????????????????
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?????????????? ???? ??????????????????????????? ????????????????-MEM. For 
???????????????????????????????????????????????????-basic, pGL3-A and 
pGL3-G, and 25ng of the phRL-TK vector were mixed with the 
Metafectene/ Opti-MEM solution and incubated at room temperature for 
?????????????????????????????????????????????????????????????????????? of a 
96-well microtiter plate. As with the Lipofectamine transfection, for every 
sample 4 separate wells were used. Four wells for phRL-TK and 4 wells 
for only Opti-MEM with Metafectene served as negative controls. The 
?????????????????????????????????????????????????????????????????????????
20% FBS was added to every sample. The plate was incubated for 
another 48 hours prior to the Luciferase Reporter Assay.
2.4.3. Preservation of Cells 
Cells were preserved for later experiments. To do so, the media was 
removed and the cells were washed once with PBS. Then, Trypsin-EDTA 
was added to release the cells from the bottom of the flask. Medium 
containing FBS was added and the whole contents of the flask were 
centrifuged at 1200rpm for 5min. The supernatant was removed and the 
cell pellet was resuspended in DMEM containing 10% DMSO. The cells 
were stored at -80°C over night and transferred to liquid nitrogen the next 
day. 
2.5. Dual-Luciferase® Reporter Assay
The Dual-Luciferase Reporter Assay was carried out to measure the 
expression level of VKORC1 in HepG2 cells with a wildtype promoter 
polymorphism (-1639G) and compare it to the expression level of the 
variant polymorphism (-1639A). The expression of two individual reporter 
enzymes is measured simultaneously. These enzymes are firefly 
(Photinus pyralis) and Renilla (Renilla reniformis) luciferase. Two liquid 
reagents are added to the sample that detect the luciferase activities and 
give a luminescent signal.
Diploma Thesis
44
Prior to the assay the cells were lysed. The growth media was removed 
??????????????????????????????????????????????????????????????ed sample
in the 24-well plate. The plate was put on a shaker for 15min. Afterwards 
??????????????????????????????????????????????-well plate which was then 
set in place in a luminometer. The two reagents necessary for the 
measurements, LAR II and Stop & Glo ® had been prepared before. In the 
?????????????????????? ??????????????????? ????????????? ???????????????????
reagent detects the activity of the firefly luciferase and generates a 
???????????????????????????????????????????????????????????????????® per 
well quenches the reaction of LAR II with the firefly luciferase and instead 
produces a luminescent signal from the Renilla luciferase.
2.6. Construction of a VKORC1 Full-Length cDNA
For the construction of the VKORC1 full-length cDNA the plasmids pGL3-
G and pGL3-A which contained the VKORC1 promoter variants were 
used. The luciferase gene present in the pGL3 vectors was removed from 
the construct and was replaced by the VKORC1 cDNA.
2.6.1. RNA Isolation and Generation of cDNA
RNA was isolated from frozen HepG2 cells (see section 2.4.3., p.45) using 
the RNeasy® Mini Kit by Qiagen. 
?????? ??? ??? frozen HepG2 cells were thawed in 2ml of Passive Lysis 
Buffer and 700?l of the resulting lysate were transferred into a 
QIAshredder spin column. To homogenize the lysate the column was 
centrifuged at 13200rpm for 2min. Afterwards the shredder was discarded 
and 1 volume of 70% ethanol was added to the flow-?????????????????????
of the sample were applied to an RNeasy spin column which was placed 
in a 2ml collection tube. The tube was centrifuged at 13200rpm for 30sec, 
the flow-through discarded, the column placed in a fresh collection tube 
and the tube centrifuged again at 13200rpm for 30sec. To remove 
contaminations the column was washed three times using wash buffers 
contained in the kit. The column was put into a fresh collection tube and 
centrifuged without addition of any reagent for 2min at 13200rpm.
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RNA was eluted by 40?l of RNase-free ddH2O to the column. Optical 
density of the sample was measured directly after isolation using a 
NanoDrop® ND-1000 spectrophotometer.
The cDNA synthesis was performed briefly as follows: starting material 
was 10ng of the RNA samples isolated before. These were incubated for 
10min at 70°C on a thermo cycler and put on ice immediately afterwards. 
They were then filled up with ddH2O to reach a total reaction volume of 
12?l.
A Mastermix Premix was prepared that contained 5x buffer at a 
concentration of 1x, dNTP Mix at a concentration of 1mM, 20pmol of Oligo 
dT Primers and DTT at a final concentration of 10mM. 23.7 Units of RNA 
Guard and 8Units of MMLV-RT were added. Of this Mastermix (MM) 
????????????????????????????????????????????for 10 min at 22°C, 45min 
?????????????????????? ??????????????????????? ????????????????????????2O 
?????????????????????????????????????????????????????????????????????
2.6.2. Control-Gene PCR
GAPDH or Glycerinaldehyd-3-phosphat-dehydrogenase served as a 
reference gene for the RNA and cDNA isolated from the HepG2 cells.
The two primers specific for the GAPDH gene were used for amplification 
at a concentration of 10pmol:
Designation Sequence 5'-3'
GAPDH Gap-f GAAGGTGAAGGTCGGAGTC
GAPDH Gap-r GGGGATGGTGATGGGATTTC
The Mastermix included: 2?l 10x PCR buffer without MgCl2 (25mM), 0.2?l 
?????????? ??????? ??????? ????????? ????? ??????????? ????? ????? ????l 
Rapid Load PCR Loading Dye and ddH2O in a total reaction volume of 
20?l. Of the undiluted cDNA 2?l were added and the PCR was performed 
with the following temperature protocol:
Denaturation for 7' at 95°C followed by 38 cycles of 30'' at 95°C, 30'' at 
60°C and 30'' at 72°C and final elongation for 10' at 72°C, cooling to 4°C.
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Fragment length was analyzed by gel electrophoresis on a 5% 
polyacrylamide gel (Criterion Gel, Bio Rad) at 175V for 45min. A 1xTBE 
MspI Marker was used.
2.6.3. Primer Design
Special primers, one forward and one reverse, were designed to include 
the restriction sites for the enzymes HindIII and XbaI into the sequence of 
the cDNA construct. The HindIII restriction sequence was positioned 
directly before the start codon and the XbaI sequence directly behind the 
stop codon of the coding sequence. The resulting primers were the 
following:
Designation Sequence 5'-3' Length
#182 VKORC1cdsfw AAGCTTATGGGCAGCACCTGGG 21bp
#183 VKORC1cdsrv TCTAGATCAGTGCCTCTTAGCCTTGCC 27bp
2.6.4. PCR Amplification of the cDNA  
For PCR amplification of the cDNA with restriction sites 10pmol of the 
primers (#182, #183) and 100ng of the cDNA were used. The other 
reagents were: 2?l 10x PfuUltra PCR buffer, 0.2?l 20mM dNTP Mix, 0.5?l 
PfuUltra Hotstart Polymerase, Loading Buffer and ddH2O to add to a total 
????????????????????????
The temperature protocol was: Denaturation for 10' at 94°, 35 cycles of 
30'' at 94°C, 30'' at 60°C and 2' at 72°C, final elongation for 7' at 72°C and 
cooling to 4°C. The amplified fragments were analyzed for right length on 
a 5% polyacrylamide gel at 175V for 45min. Again a 1xTBE MspI Marker 
was used.
2.6.5. DNA Extraction from Agarose Gel
To minimize the risk of ligating a possibly wrong fragment into the vectors, 
the right PCR product was extracted from an agrose gel.
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The gel slice was transferred into a small reaction tube, weighed, 3 
????????????????????????????????????????????????????????????????????????
mixture was then incubated for 10min at 50°C and vortexed every 2-3min. 
At the end of the incubation time the gel was completely dissolved. 
Following the addition of 1 volume of isopropanol the sample was 
transferred to a QIAquick spin column which was placed in a 2ml 
collection tube and was centrifuged for 1min at 13000rpm. The flow-
through was discarded and the column put back into the tube. 0.5ml of 
buffer QG were added and the column was centrifuged again at 13000rpm 
for 1min to remove residual agarose. The DNA should by now be inside 
the column membrane. To wash the DNA 0.75ml of buffer PE were added 
and the tube was again centrifuged for 1min. The flow-through was 
discarded and the column centrifuged for an additional 1min to remove all 
traces of the flow-??????????????????????????????????????????????????????
2.6.6. Restriction Enzyme Digestion of Plasmids and 
cDNA
The VKORC1 full-length PCR product, the plasmid pGL3-A and the 
plasmid pGL3-G were linearized by restriction enzyme digestion with 
HindIII and XbaI. Double digestion also ensures that the cDNA is later 
inserted in the right direction into the vector during ligation.
The digestion was carried out according to the protocol by Roche Applied 
Biosystems.
One Unit of each enzyme was mixed with 25?l of Buffer B. For every 
restriction 2.5?l of this mix was used. For digestion of the plasmids 1?g of 
pGL3-G and pGL-A was used, for digestion of the full-length PCR product 
1.2?g were used. The reaction volumes were filled up with ddH2???????????
The samples were incubated on a thermo cycler at 37°C for 1 hour. 
The digested plasmids were separated by agarose electrophoresis at 
100V for 60min, and the bands corresponding to the correct fragment 
length were extracted with the QIAquick Gel Extraction Kit.
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2.6.7. Ligation 
The ligation of insert and vectors was performed with the Rapid DNA 
Ligation & Transformation Kit by Fermentas. 
???? ???? ????????? ????? ????????? ???????? ????? ????? ????? ?????????? ????
ligase, ligation buffer, vector and insert. 70ng of pGL3-A and pGL3-G 
vector were mixed with 40ng of PCR product and 5U of T4 DNA Ligase 
(1?l). 4?l of 5x Rapid DNA Ligation buffer were added to reach a final 
??????????????????????????????????????????????????????????????????????????
thermo cycler for 5min. The products were analyzed on a 0.8% agarose 
gel at 100V for 90min. A High Range DNA Ladder was used to determine 
the lengths of the bands. 
Transformation into bacterial cells was performed immediately afterwards. 
2.6.8. Transformation into Bacterial Cells
For the transformation of the ligated plasmid constructs, chemically 
??????????????? ??????????? ????? ?????????? ?????????? ??? ???? ???????r the 
transformation a very short protocol was used. For each ligation product 
????????????????????????????????????????????????????????????????????????
???????????? ??????? ????????????? ???? ??? ???? ????????? ???????? ???? ???????
The reaction tubes were then put on a shaker that had been pre warmed 
to 37°C for 10min. After this incubation time the whole amount of the 
transformation products was plated out on pre warmed LB agar plates 
??????????????????????????????????????????????????????????????????????????
for 12-16 hours.
2.6.8.1. Colony PCR
Selected colonies were tested by PCR to evaluate if the right insert had 
been ligated into the vectors. The PCR MM contained 10x GoldTaq Buffer, 
25mM MgCl2, 5x PCR Loading Dye, 20mM dNTPs, 0.5U AmpliTaq Gold 
Polymerase, ddH2O, and 10pmol of each of the two primers that were 
specially designed to amplify the VKORC1 full-length construct. Colonies 
were picked and added ??? ????? ???? ???? ?????????????? ???? ??????????
using the following temperature protocol: Denaturation for 10' at 94°C 
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followed by 35 cycles of 45'' at 94°C, 45'' at 60°C and 2' at 72°C and final 
elongation for 7' at 72°C. The samples were cooled down to 4°C. The 
products were tested on 5% polyacrylamide gels (Criterion, BioRad) at 
175V for 45min.
Colonies containing the right plasmid were picked again and used to 
inoculate a 2ml LB medium aliquot which was incubated at 37°C for about 
16 hours. Subsequently plasmid DNA isolation was carried out with the 
QIAPrep Spin Miniprep Kit by QIAGEN (for procedure see section 2.1.1., 
p. 35). Gel electrophoresis was performed on a 0.8% agarose gel at 100V 
for 60min.
2.7. VKORC1 Full-Length Construct
2.7.1. Restriction Enzyme Digestion
Three different restriction enzyme digestions were performed to test if the 
selected insert was taken up by the vector and was present in the 
plasmids. Three different restriction enzyme digests were set up; 
combined digestion with the restriction enzymes HindIII and XbaI, 
digestion with HindIII and digestion with XbaI only. For the double 
digestions an enzyme mix wa?????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????
to 800ng of the plasmid and filled up with ddH2????????????????????????????
For the single digestions of each vector 800ng were mixed with 1Unit of 
???????? ??? ????? ?????? ??? ?????? ???? ?????? ????????? ??????? ??? ????? ????
obtained by the addition of ddH2O.
Following incubation at 37°C for 1hour the fragment length was checked 
on a 0.8% agarose gel running at 100V for 60min. Again a High Range 
Marker was used.
2.7.2. PCR
To test whether the promoter sequence and the VKORC1 coding 
sequence are present in the plasmid three different PCR mastermixes with 
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different primers were prepared. The first MM contained the VKORC1 c-fw 
primer for the promoter and the rev primer complimentary to a sequence in 
the VKORC1 cDNA. If the VKOR cDNA was successfully inserted 
adjacent to the promoter these two primers should produce a fragment of 
around 2200bp. 
The second MM contained forward and reverse primers for the promoter 
element. This reaction served as a positive control. 
The third MM contained forward and reverse primers for the VKORC1 
coding sequence. This reaction also served as a positive control.
The PCRs were all performed in a reaction volume of 20??:
1. 12.4??? ddH2O, 2?l 10x GoldTaq Buffer, 1.5?l 25mM MgCl2, 0.8?l 5x 
Rapid Loading Buffer, 0.2?l dNTP Mix, 1?l #183 VKORC1cdsrv (10pmol/ 
?l), 0.4?l #85 VKOR -1639 c-fw (10pmol/ ?l), 0.1?l GoldTaq Polymerase 
(5U/ ?l) and 1?l plasmid (~12.5ng).
Primer Sequence 5'-3'
#183 VKORC1cdsrv TCTAGATCAGTGCCTCTTAGCCTTGCC
#85 VKOR -1639 c-fw ACAGTAAGGGATCCCTCTGGGAAGTC
PCR temperature protocol:
10' at 94°C, 35 cycles of 45'' at 94°C, 45'' at 60°C and 2' at 72°C, 7' at 
72°C.
2. 12.4 ?l ddH2O, 2?l 10x GoldTaq Buffer, 1.5?l 25mM MgCl2, 0.8?l 5x 
Rapid Loading Buffer, 0.2?l dNTP Mix, 0.5?l #83 VKOR -1639 w-rv 
(10pmol/ ?l), 0.8?l #84 VKOR -1639 mut-rev (10pmol/ ?l), 0.4?l #85 VKOR 
-1639 c-fw (10pmol/ ?l), 0.1?l GoldTaq Polymerase (5U/ ?l) and 1?l 
plasmid (~12.5ng).
Primer  Sequence 5'-3'
#85 VKOR -1639 c-fw ACAGTAAGGGATCCCTCTGGGAAGTC
#84 VKOR -1639 mut-rv AGGATTATTAGCGTGAGCCACCGCTCCT
#83 VKOR -1639 w-rv AGGCGTGAGCCACCGCAACC
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PCR temperature protocol:
10' at 94°C, 35 cycles of 45'' at 94°C, 45'' at 60°C and 2' at 72°C, 7' at 
72°C.
3. 12.4?l ddH2O, 2?l 10x GoldTaq Buffer, 1.5?l 25mM MgCl2, 0.8?l 5x 
Rapid Loading Buffer, 0.2?l dNTP Mix, 1?l #182 VKORC1cdsfw (10pmol/ 
l), 1?l #183 VKORC1cdsrv (10pmol/ ?l), 0.1?l GoldTaq Polymerase (5U/ 
?l) and 1?l plasmid (~12.5ng).
Primer Sequence 5'-3'
#182 VKORC1cdsfw AAGCTTATGGGCAGCACCTGGG
#183 VKORC1cdsrv TCTAGATCAGTGCCTCTTAGCCTTGCC
PCR temperature protocol:
10' at 94°C, 35 cycles of 45'' at 94°C, 45'' at 60°C and 2' at 72°C, 7' at 
72°C.
All PCR products were subsequently analyzed on a 5% Criterion gel at 
175V for 45min using a 1xTBE MspI Marker.
2.7.3. Sequencing
To identify the sequence of the two plasmids cycle sequencing was 
performed using the following primers:
Primer Sequence 5'-3'
#182 VKORC1cdsfw AAGCTTATGGGCAGCACCTGGG
#183 VKORC1cdsrev TCTAGATCAGTGCCTCTTAGCCTTGCC
VKORC1 5'UTR 5fw TCGCTGTTTTCCTAACTCG
Primers were used at a concentration of 5pmol. The plasmid DNA 
concentration was 25ng. 
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The reactions were prepared in a 96-well plate with 2?l Big Dye 
Sequencing Buffer (5x), 0.4?l Big Dye Terminator Mix and deionized 
??????????????????????????????????????????????
The sequencing PCR was performed in a PE 9700 Thermal Cycler with 
the following temperature protocol: Denaturation for 1' at 96°C, 25 cycles 
of 10'' at 96°C, 5'' at 50°C, 4' at 60°C and cooling to 4°C.
The sequences were analysed on an ABI PRISM® 3100 Genetic Analyser.
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V. RESULTS
1. Plasmid Recovery
1.1. Miniprep
When the frozen plasmid Glycerol stocks were reactivated and the 
isolated plasmids were analyzed by agarose gel electrophoresis after 
Miniprep and restriction enzyme digestion, it was observed that some 
plasmid molecules migrated with a longer fragment length than expected. 
The expected size of the inserted promoter region should be about 1700kb
but was actually near 4000kb compared to the High Range DNA marker. 
This phenomenon was observed for the wild type as well as variant 
promoter construct.
We suspected that in some vectors the promoter segment had been 
inserted more than once in tandem fashion. For further experiments, only 
plasmids were chosen that migrated with the correct length. 
With the new plasmids fresh glycerol stocks were prepared. 
1.2. Sequencing
Clear sequences were obtained with low background noise. Expectedly, 
the two plasmids differed only by the one base that constitutes the 
polymorphism -1639G>A. The wild type sequence contained a G at the 
position -1639, the variant showed the base A in the same place.
2. Dual Luciferase® Reporter Assay
For the Dual Luciferase Reporter Assay HepG2 cells were transfected with 
plasmids pGL3-G and pGL3-A 48 hours prior to the performance of the 
assay. According to our results, the effect of the promoter variant on the 
expression of luciferase activity in HepG2 cells seemed to depend on the
transfection method used. Following transfection with lipofectamine the 
promoter variant pGL3-A induced a higher luciferase activity while with 
Metafectene the pGL3-G promoter sequence induced the higher luciferase 
activity. The reason for these discrepant finding is currently unclear. 
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2.1. Lipofectamine™ 2000
Using lipofectamine as transfection reagent the luminescence signals 
were low and differed considerably between samples even though all 
samples were transfected under the same conditions.
No treatment PGL3 basic pGL3-G pGL3-A
0.2 3 0 13
-1 1 -10.5 138
3.333 4 49 -11
1.333 -1 -17.75 0
5.188 35
0 0 -39.5 -37.5
1.5 -1 6 42
0 0 27.929 70
0.25 -3.5 27 26.5
5.357 25.25
5.273 30.125
Table 3. Relative Luminescence Values following Transfection with 
Lipofectamine
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Using lipofection, the pGL3-A promoter construct induced an 83% higher 
luciferase activity compared to the pGL3-G construct in HepG2 cells. 
However, the transfection efficiency was very low and the data were highly 
variable. The results indicate that transfection of HepG2 cells using 
Lipofectamine does not give reliable results. Apparently, transfection is not 
always successful and cells do not always take up the construct. For our 
plasmid and HepG2 cells lipofection was not suitable.
2.2. Metafectene™ PRO
The transfection was repeated with the new transfection reagent 
Metafectene PRO which is described by the manufacturer as reagent 
suitable for hard-to-transfect cells. 
The luminescence signals obtained with Metafectene were much higher 
than those obtained using lipofection but still differed between samples. 
Transfection efficiency was more consistent but still variable.
pGL3G pGL3A
Vector
-40,000
0,000
40,000
80,000
120,000
R
LU
Transfection with Lipofectamine
Fig.5. Relative Luminescence of cells transfected with 
Lipofectamine
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No treatment PGL3 basic pGL3-G pGL3-A
0.004 1.119 400.078 361.352
-0.002 4.25 194.648 149.893
0.005 1.334 163.981 409.693
252.902 306.979
-0.004 2.267 641.107 282.195
-0.001 2.257 73.679 312.552
-0.002 0.681 333.702 102.233
-0.002 0.925 283.996 616.266
333.121 328.312
0.002 0.157 70.252 63.808
0 0.518 43.897 27.565
-0.004 0.158 15.665 35.4
0.003 0.498 206.036 55.155
83.963 45.482
-0.001 0.65 63.396 92.195
0.002 0.276 112.542 34.103
0.001 0.997 59.184 72.212
0.01 0.272 254.473 55.685
122.398 63.548
198.096 186.080
Table 4. Relative Luminescence Values for the Transfection with Metafectene
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With Metafectene as transfection reagent the pGL3-G promoter construct 
induced only a 6% higher luciferase activity compared to the pGL3-A 
construct. This is not a significant difference.
According to my results the variations at -1639 of the VKORC1 promoter 
does not seem to have a significant effect on the expression of luciferase 
activity in HepG2 cells.
pGL3G pGL3A
Vector
0,000
200,000
400,000
600,000
R
LU
A
Transfection with Metafectene PRO
Fig.6. Relative Luminescence by cells transfected 
with Metafectene
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2.3. Comparison of the Transfection Reagents
Lipofectamine 2000 Metafectene PRO
TransfectionReagent
0,000
200,000
400,000
600,000
pG
L3
G
AA
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
Lipofectamine 2000 Metafectene PRO
TransfectionReagent
0,000
200,000
400,000
600,000
pG
L3
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
AA
A
A
A
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The comparison of the two transfection methods shows that transfection of 
HepG2 cells with Metafectene is more efficient for pGL3-A and pGL3-G 
than using lipofection. Nevertheless, the quadruplicate tests indicate a 
high variability of the performance of each Metafectene transfection. 
Possibly, modifications of the protocol could improve the transfection 
efficiency.
3. Generating a VKORC1 Full-Length Construct
3.1. VKORC1 Coding Region cDNA with Restriction 
Sites
Fig.9. shows the PCR products obtained by amplification of the cDNA with 
the primers containing the restriction sequences of HindIII and XbaI.
Marker: pBR322 
MspI
622
527
404
307
I observed that two PCR fragments were generated. The upper band 
represented the expected fragment which has a length of 504bp, made up 
of 492bp for the VKORC1 coding region and 6bp for each of the two 
restriction sites. The shorter band shows a fragment length of about 
380bp. 
A partially complementary sequence to the forward primer was identified 
about 100bp within the coding sequence of VKORC1. Even though only a 
Fig.9. Fragments generated by PCR 
amplification of cDNA with 
restriction sites
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few bases corresponded with the selected primer, this was sufficient to 
generate a second binding site. 
The use of different annealing temperatures did not change the results. 
Other modifications such as a surplus of the reverse primer also did not 
prevent the generation of the second fragment. Thus, the correct fragment 
was excised and extracted from the agarose gel prior to further use.
3.2. Linearising of the Plasmid Vectors and Removal 
of the Luciferase Gene
Linearising of the plasmid vectors and removal of the luciferase gene was 
accomplished by restriction enzyme digestion with HindIII and XbaI and as 
confirmed by gel electrophoresis. The gel picture showed fragments with a 
length of around 4818bp which corresponds to the right size.
3.3. Ligation of the VKORC1 Coding Region into 
Plasmid Vectors
The success of the ligation was examined by gel electrophoresis following 
digestion with HindIII and XbaI.
Fig.10. shows undigested and digested plasmids. In slots number 3 and 8 
the bands for pGL3-G and pGL3-A digested with both HindIII and XbaI can 
be seen. The upper band at around 4800bp represents the linearised 
vectors. No band is visible for the insert, yet there is a second band at 
about 1800bp.
High Range 
Marker
10 000
4 000
2 000
1 000
500
Fig.10. Slot1: Marker, Slot2: pGL3-G undigested, Slot3: pGL3-
G double digested, Slot4: pGL3-G digested with HindIII, 
Slot5: pGL3-G digested with XbaI, Slot7: pGL3-A undigested, 
Slot8: pGL3-A double digested, Slot9: pGL3-A digested with 
HindIII, Slot10: pGL3-A digested with XbaI
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4. Revision of VKORC1 Full-Length Construct
4.1. PCR Amplification and Gel Electrophoresis
Fig.11., 12. and 13. show the results of the three PCR reactions performed 
to check if the insert was present in the constructs and if it was integrated 
adjacent to the promoter instead of the luciferase gene. 
622   
527   
404   
307   
The gel in Fig.11 shows two bands, one at about 400-500bp and one in 
the high molecular weight range – top of the gel, difficult to see. The photo 
shows a polyacrylamide gel for which the standard marker is the MspI
marker with the highest band at 622bp. A correct estimation of the length 
of this fragment was not possible because the product was out of the
range of the markers used. The expected length of the PCR product 
should be about 2200bp. While the upper band could represent the right 
fragment the source of the smaller band was unclear – such a band 
should not be there.
To determine the length of the high molecular weight product the 
electrophoresis was repeated on an agarose gel using a High Range 
marker but this time, only the smaller product was visible.
Fig.11. PCR 
results for 
promoter fw 
primer and 
insert rev 
primer
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527
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Fig.12. PCR results with 
insert primers 
In Fig.12 in slot number four two bands can be seen. The upper band at 
around 500bp represents the insert, the shorter fragment at about 380bp 
is the product generated by the binding site of the fw primer within the 
sequence. 
160   
147   
123   
110   
90   
Fig.13 shows the PCR products for the PCR with only the promoter 
primers. In slot number two the band for the wild type promoter pGL3-G 
with a length of 82bp can be seen, in slot three the band for the promoter 
of the construct pGL3-A with a length of 88bp is visible.
Fig.13. PCR 
results with 
promoter primers
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4.2. Sequencing
Sequence analysis of the constructs indicated incorrect sequences. A 
DNA fragment corresponding to part of the luciferase gene was identified 
between the VKORC1 promoter and the VKORC1 cDNA.
Apparently, the restriction enzyme digestion did not remove all of the 
luciferase gene sequence. A part of the sequence of the luciferase gene 
remained in the construct. To my surprise, the luciferase gene sequence 
was followed by a sequence that does not correspond with the VKORC1 
promoter nor the VKORC1 cDNA nor the luciferase gene.
To determine to which gene this sequence was corresponding I did a blast 
search using the internet platform NCBI. No similarity to any sequences in 
this database could be found neither in forward nor reverse orientation. 
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VI. DISCUSSION
The enzyme VKORC1 is the rate-limiting factor of the vitamin K cycle. Its 
availability is vital for the carboxylation of the VKD proteins which gurantee 
the proper function of the blood coagulation system. If the carboxylation of 
the VKD proteins is disturbed because of deficiencies in the expression of 
VKORC1, cardiovascular diseases, thromboembolic events and even 
osteoporosis can develop as a result. Some of these diseases can be 
treated or prevented by medication with anticoagulants such as warfarin.
In the course of this diploma thesis I tried to conduct similar experiments 
as Yuan et al.52 to see if I was able to reproduce and maybe re-evaluate 
their results. I also used a HepG2 cell line, carried out transfection with 
Lipofectamine™ 2000 and analysed the constructs in a Reporter Gene 
Assay.
The reagent Lipofectamine proved unsuitable for this reaction as 
transfection efficiency was very low and highly variable. The values 
differed considerably from one assay to the next. The average expression 
promoted by the A allele was approximately 83% higher than by the G 
allele. If the results were reliable, this would be a contradiction to the 
results reported by Yuan et al. However, as the luciferase activity levels 
were so variable, I decided not to trust the values and instead chose to try 
another transfection reagent. 
Metafectene™ PRO, a new and improved reagent appeared to be a very 
reliable product as it had higher transfection efficiency and therefore the 
values I obtained from the luciferase assay also were much higher. 
Although the results were still quite variable, I was able to use them for 
calculating the difference in expression levels between the SNP -1639G 
and -1639A. I found that the expression of the cells transfected with the -
1639G promoter construct was only 6% higher than of those with the 
variant -1639A. This difference is not statistically significant which means 
that according to my experiments the SNP G-1639A does not have a
significant influence on the promoter activity and expression of the 
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VKORC1 gene in HepG2 cells. These results disagree with those of Yuan 
et al. but agree with the findings of Bodin et al.
One of my fellow students at the KIMCL worked on a project very similar 
to mine. She conducted the same experiments but used osteoblasts 
instead of HepG2 cells and also experienced difficulties transfecting her 
cell line with Lipofectamine as transfection reagent. With Metafectene she 
was able to show a higher promoter activity of the VKORC1 G construct 
compared to the A variant.
Comparing these results to my own I draw two conclusions:
Firstly, Lipofectamine™ 2000 seems to be an unsuitable transfection 
reagent for HepG2 cells and I would recommend that scientist preferably 
use other methods for transfection of these cells.
Secondly, I suspect that the effect of the promoter polymorphism G-1639A 
is tissue-specific since it was observed that it does have an influence on 
the expression of the VKORC1 gene in osteoblasts but not in HepG2 cells.
The experiments I conducted in the first part of this diploma thesis focused 
on VKORC1 constructs that contained only the promoter of the gene with 
the SNP. In these constructs the promoter drove the expression of the 
luciferase gene and the resulting expression was measured in the Dual 
Luciferase Reporter Assay.
To find out if the results are different if the VKORC1 gene coding 
sequence is present in the construct and is regulated by the promoter we 
decided to prepare a construct containing the promoter and the VKORC1 
cDNA. We chose to remove the luciferase from our plasmid DNA and 
replace it by coding region of the VKORC1 gene. 
Producing the full length constructs proved to be a very complicated 
process. Several modifications were necessary to obtain the full length 
cDNA and ligate it with the promoter contained in the plasmid. Eventually, 
constructs were available and could be examined. Interestingly, I
discovered that only parts of the luciferase gene had been removed by the 
restriction enzymes but some luciferase fragments were still present in the 
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construct. Surprisingly, the VKORC1 coding region sequence was not 
detectable adjacent to the promoter nor adjacent to the luciferase 
sequence. Even more astounding was the fact that the sequence 
corresponding to the luciferase was followed by an unidentifiable
sequence that does not resemble any human gene sequence. 
Thus, it was amazing that the VKORC1 cDNA could be amplified from the 
plasmid DNA by PCR. Possibly, it was built into the vector in the wrong 
place. Another explanation could be that the sequence of 500bp is too 
short and makes the vector unstable. Up to date it remains unclear to 
which gene or part of a gene the unidentifiable sequence corresponds. For 
time reasons, I was not able to test whether this sequence was already 
present in the luciferase vector. Such a control experiment should clarify 
whether the observed sequence was coming from the vector and whether 
the VKORC1 cDNA was integrated behind the segment luciferase/
unknown sequence instead of adjacent to the promoter. For the time being 
I want to conclude from my work that another strategy for the production of 
a promoter – cDNA construct of the VKOR gene has to be used.
In 2008 Wang et al.48 prepared a construct. They used the complete 
VKORC1 gene to generate a transfectable construct and they succeeded. 
Presumably, the whole gene has to be used and the coding region alone 
is just not enough.
In conclusion, I believe that the results one can obtain from a reporter 
gene assay for the VKORC1 promoter function, eg using a Luciferase 
assay, are only partly meaningful because the promoter seems to be 
tissue dependent and this may not be completely reflected by the 
Luciferase assay. To study the regulation and function of VKORC1 in 
different cell populations one should produce full length VKORC1 
constructs composed of promoter, exons and introns of the gene. To 
obtain such constructs one could follow the protocol reported by Wang et 
al.48
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VII. APPENDIX
1. VKORC1 Full Sequence
VKORC1 Color FASTA, available at 
http://pga.gs.washington.edu/data/vkorc1/vkorc1.ColorFasta.html
CAGAGGACAA CATAGATAGG TTCGGAGACT ACTCAGAGAA AGGGAGAGAG 50
AATGCTAGGT TATCTTTCAG CTGTTTTAGC TGCTTATTGT TCCAGCTTTA 100 | REPEAT
GCCACCATCT GACTGCAATT GTATGAGCCA GAAATAGCCA GGTAAAATTG 150
TCTTCCCAAA TTCCTAGTGC ACAAAAACTG TCAGAGGCTG GGGGCAGTGG 200 | REPEAT
CTCACTCCTG TAATCCCAGC AGCACTTTGG GAAGCCAGGG TGGGAGAACT 250
GCTTGAGCCC AGGAGTTAGA GGCAACATAA CAACAACTCA TCTCTAATGA 300 | var(298):[C:0.01]
AAAAAAAAAA AAAAGAAAGA AAAAGGCCAG GCACAGTGGC TCACGCCTGT 350 | REPEAT
AATCCCAGCA CTTTAGGAAG CCAAGGAGGG TGGATCATGA GGTCAGGAGT 400 | var(381):[C:0.47]
TTGAGACCAG CCTGGCCAAT ATGGTGAAAC CCCGTCTCTA CTAAAAACAC 450
AAAAATCAGC CACGCATAGT GGCTGGTGCC TGTAATCACA GCTACTCAGG 500
AGGCTAAGGC AGGAGAATCA CTTGAATCCG GGAGGCAGAG GTTGCAGTGA 550
GCCGAGATTG CACCACTGCA TTTCAGCCTG GGCAGCAGAG TGGGACTGTC 600
TCACATTAAT TAATTAATTG ATTAAATGCT AGAAGAAAAT ATGGTCAAAA 650
TCTTTTATAA CTCTTGGAGT GAGGAAGGCA ATCTCGGCTC ACTACAACTT 700 | REPEAT
CCACCTCCCG GGTTCAAATG ATTCTCCTGC CTCAGCCTCC TGAGTAGCTG 750 | var(740):[T:0.01]
GGATTACAGG CACCCACCAC CATGCCCGGC TAATTTTTGT ATTTTTAGTA 800
GAGACGAGGT TTCGCCATGT TGGCCAAGCT TGTCTTAAAC TCCTGACCTC 850
AGGTGATCCA CCCACCTCAG CCTCCCAAAT TGCTGGGATT ACAGGCATGA 900 | var(861):[A:0.26]
GCCACCATGC CCCGCCTAAT TTTAAAAATG TTTATAAAGA CAGAGTCTTA 950
CCACGTTGTC CAGACCTGTC TCAAACTCCT GGGCTCAAGT CATTGTCTTG 1000 | REPEAT
TCTCAGCCTC CCAAAGTTCT GGGACTACAG GTGTGCACCA CCACACCTGG 1050
CTAATTTTGT TTATTTTTTA TAGAGTGAGG GTCTCCCTGT GTTGTCCAGG 1100
GTGTCTCAAA CTCCTGGGCT CAAGTGGTCC TCCTGCCTCA GCCTCCCAAA 1150
GTGCTGGGAT TATAGGCATA AGCCACTGCA CCTGGCCCCA GTGTGTGTCT 1200 | REPEAT
TCTGAGGCTA AGTCATAAAG AGATTGCGGC TTCTATTTTG CTTCCTCTTA 1250
GATCACTCAT TCTGGGGGAA ACCAACAATA AATAACAGGA ACACACCAGG 1300
AGATCAGAGA AAGCTGAGAT ACAGGCCTAA TGCCCAGTCC TCTGTATTCA 1350 | REPEAT
TTTCTAATTG CTGCTGTAAC AAGTTACTGC ACATTTAATG ATGTAAAACA 1400
ACACAAATTT ATCTTACAGT TCTGTAGCTT AGAAGTCTGA CAGAGTCTCA 1450
CTGGGCTGAA ATCAAGATGT TGATAGTTCC TTCCCGGTGA CTCTAGAGTG 1500
AGAATCCAGT TCTTTACCCT TTCTTGCCTT TAGAGGCCAC CCGTATTTAT 1550
TAGCTCACAA TCCCCTTCCT CCATCTTCAA ACCAGAAACA TTGCAGCTCT 1600
CTGTGTCTTT TTTCTTTACT CACATCTCCC TCTGACTTTC TTCTGCCATC 1650
CTCCTTCATT TTTTAAGGAC CCCTGTGGGC CAGGCATGGT GGCTTATGCC 1700 | REPEAT
TGTAATCCCA GCACTTTGAG AGGCGGAGGC AGGCGGGTCA CCTGAGGTCA 1750
GGAGTTCCAG ACCAGCCTGG CCAACATGGC AAAACCCCAT CTCCACTGAA 1800
AATACAAAAA TTGGGCCAGG CACGGCGGCT CACACCCGTA ATCCCCATAC 1850 | REPEAT
TTTGAGAGGC TGAGGCAGGT GGATCACTTG AGGTCAGGAG TTCAAGACCA 1900
GCCTGGCCAA CATGGTGAAA TCCCGTCTCT ACTAAAAAAA AAAAAAATTA 1950 | NOT SCANNED
CAATAATTAG TCAGGCGTGG TGGCCAGCAC CTATAATCCC AGCTACTTGG 2000
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GAGGTTGAGG CACAAGAATT GCTTGAACCC GAGAGGGGGA GGTTGCAGTG 2050
AGCTGAGATT GCACCACCGT ACTCCAGCCT GGATGACAGA GCAAGACTCT 2100
GTCTCAAAAT AAAAATTAAG ATAAATAATA AAAAATAAAT AAAAATCAGC 2150 | REPEAT
AAATTAGGCC AGGTGTGGTG GTGGCTCATG CCTGTACTCC CAGCACTTTG 2200 | REPEAT
AGGTGGGAAG GTTGCTTGAA ACCAGAAGTT TAGACCAGCC TGGGAAACAA 2250
AGTGAGACCC CATCTCTACA AAAATAAAAA TAAATTAGCC AGGTGTGGTG 2300
GGACGTACTT GTACTCCTAG CTACTAGGGA GGCTGAGGTG CAAGAATCGC 2350
TTGAACCTGG GAGACGGAGG TTGCAGTGAG TTATGACAGT GCCACTACAC 2400
TCCAGCCTGG GTGTCAAGGG TCTTTGAAAA AATAAACAAA ATAGGCTGGG 2450 | REPEAT
CGTGGTGGCT TACACTTGTA ATCCCAGCAC TTTGGGAGGC TGAGGCAGGC 2500
AGATCACAAA GTCAGGAGTT CGAGACCAGC CTGGCCAACA CAGTGAAACC 2550
CCGTCTCTAC TAAAAATACA AAAATTAGCC AGGCATGGTT GCACGCGCCT 2600
GTAGTCCCAA CTGCTCGGGA GGCTGAGGCA GGAGAATGGC TTGAACCTGG 2650
GGGGGGGCGG AAGTTATAAT GAGCCAAGAT TGTGCCACTG CACTCCAGCC 2700 | var(2653):[C:0.17]
TAGGCAACAG AGCGAGACTC CGTCTCAAAA ATAAAAATAA AAATAAATCA 2750
ATAGAGCCTG GTATGATGGC TCACGCCTAT AATCCCAGCA CTTTGGGAGG 2800 | REPEAT
CCCAGGTGGG TGGATCATCT GAGGTCAGGA GTTTGAGACC AGCCTGACCA 2850
ACATGGAGAA ACCCCATCTC TACTAAAAAT ACAAAAAATT AGCCAGGCGT 2900
GGTGGCACAT GCCTATAATC CCAGCTACTC AGGAGCCTGA GGCAGGAGAA 2950
TCGCTTTAAC CGGGGAGGTG GAGGTTGCGG TGAGTCGAGA TAGCACCATT 3000
GCATTCTAGC CTGGGCAACA AGAGCAAAAC TCCATCTCAA AAATAAATAA 3050
ATAAATAGAT AGATAGGCTG GGCACGGTGG CTCACGCCTG TAATCCCAGC 3100 | REPEAT
ACTTTGGGAG GCCGAGGTGG GCGGATCACC TGAGGTCAGG AGTTCAAGAC 3150
CAGCCTGGCC AATATAGCGA AACCCTGTCT CTACTAAAAA TTTAAAAAAT 3200
TAGCCAGGCA TGATGGCGGG TGCCTGTAAT CCCAGCTACT CGGGAGGCTG 3250
AGGCAGGAGA ATCTCTCGAA CCTGGCAGGC GGAGGTTGCA GTGAGCCGAG 3300
ATCACACCAT TGCACTCCAG TTGGGCAACA AGAGCGAAAC TCCACCTCAA 3350
AAACAAAATA AAATAAAATA AAATCAGGAG ATTGGTCAGC TTAATTCCAT 3400 | REPEAT
CTGCAACCTT AATTCCCTTT TGGCCATTTA ACCTATCATA TTCACAAGTT 3450 | var(3435):[G:0.14]
CCAGGGATTC ATGCAGGGAC ATCTTTGGTG ACCATTATTC TGTCTACCAC 3500
ACTCTCTAGA AGAGAGTAGA TGTGAGAAAC AGCATCTGGA GAGGGAGGAG 3550 | REPEAT
CCAGCAGGAG AGGGAAATAT CACAGACGCC AGAGGAAGAG AGTTCCCAGA 3600
AGGGTAGGTG CAACAGTAAG GGATCCCTCT GGGAAGTCAA GCAAGAGAAG 3650 3673G>A-com-fw
ACCTGAAAAA CAACCATTGG CCGGGTGCGG TGGCTCACGC CTATAATCCT 3700 | REPEAT |
var(3673):[A:0.29] 3673G>A-wt-rev 3673G>A-mut-rev
AGCATTTTGG GAGGCCGAGG TGGGTGGATC ACTTGAGGTC AGGAGTTTAA 3750
GACAAGCCTG GCCAACATGG TGAAACCCTG TCTCTACTAA AAATACAAAA 3800
ATTAGCCAGA CATGGTGGCA GGCACCTGTA GTCCAAACTA CTTGGGAGGC 3850
TGAGGCACGA GAACCACTTG AACCCTGGAG GCGGAAGTTG CAGTGAGCCG 3900
AGATGGCACC GCTGCACTCC AGCCTGGGCG ACAGAGTGAG ACTCCGTCTC 3950
AAAATAAGTA AATAAATAAA TAAATAACCA TTGGGTCTAG CGTCTTGGTG 4000 | REPEAT
ACACCAGCCA CTAGGTGTCA GGGCAATGCT GGAGGCAGCA GCTAGTTTAT 4050
GGCGTGGGCA GCAAGGAAGA AGTGAGGAAG TAGAGACTGG GAGTGTAGAA 4100
TCTTTCCAAA AACTTGAATG TGGAGGGGTA GATGGGATAA TGCCGGGAGA 4150
GGAGGCTGGT GAAGGACCTC TTAGTGAAGG GAGATTTGTT GCTGTTTCTG 4200
AGATGGGAAA GAGAAACAAG TTGCAGTGTA GATGGGGAGG ATGGAGAGGT 4250
TGAAGGTGTA GGAGAGATGG GTCACCATCA GATGGGACGT CTGTGAAGGA 4300
GAGACCTCAT CTGGCCCACA GCTTGGAAAG GAGAGACTGA CTGTTGAGTT 4350
GATGCAAGCT CAGGTGTTGC CAGGCGGGCG CCATGATAGT AGAGAGGTTA 4400
GGATACTGTC AAGGGTGTGT GTGGCCAAAG GAGTGGTTCT GTGAATGTAT 4450
GGGAGAAAGG GAGACCGACC ACCAGGAAGC ACTGGTGAGG CAGGACCCGG 4500
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GAGGATGGGA GGCTGCAGCC CGAATGGTGC CTGAAATAGT TTCAGGGGAA 4550
ATGCTTGGTT CCCGAATCGG ATCGCCGTAT TCGCTGGATC CCCTGATCCG 4600 5’UTR-fw
CTGGTCTCTA GGTCCCGGAT GCTGCAATTC TTACAACAGG ACTTGGCATA 4650
GGGTAAGCGC AAATGCTGTT AACCACACTA ACACACTTTT TTTTTTCTTT 4700 | REPEAT
TTTTTTTTTG AGACAGAGTC TCACTCTGTC GGCCTGGCTG GAGTGCAGTG 4750 | var(4719):[C:0.02]
GCACGATCTC GGCTCACTGC AACCTCCGGC TCCCCGGCTC AAGCAATTCT 4800
CCTGCCTCAG CCTCCCGAGT AGCTGGGATT ACAGGCATGT GCCACCACGC 4850 | var(4835):[A:0.01] |
var(4845):[A:0.01]
CCGGCTAATT TTTGTATTTT TAGTTGAGAT GGGGTTTCAC CATGTTGGCG 4900
AGGCTGGTCT TGAACTCCTG ACCTCAGGTA ATCCGCCAGC CTCGGCCTCC 4950
CAAAGTGCTG GGATTACAAG CGTGAGCCAC CGTGCCCGGC CAACAGTTTT 5000
TAAATCTGTG GAGACTTCAT TTCCCTTGAT GCCTTGCAGC CGCGCCGACT 5050
ACAACTCCCA TCATGCCTGG CAGCCGCTGG GGCCGCGATT CCGCACGTCC 5100 | Exon 1 | UTR
CTTACCCGCT TCACTAGTCC CGGCATTCTT CGCTGTTTTC CTAACTCGCC 5150
CGCTTGACTA GCGCCCTGGA ACAGCCATTT GGGTCGTGGA GTGCGAGCAC 5200
GGCCGGCCAA TCGCCGAGTC AGAGGGCCAG GAGGGGCGCG GCCATTCGCC 5250
GCCCGGCCCC TGCTCCGTGG CTGGTTTTCT CCGCGGGCGC CTCGGGCGGA 5300 E1-fw
ACCTGGAGAT AATGGGCAGC ACCTGGGGGA GCCCTGGCTG GGTGCGGCTC 5350
M G S T W G S P G W V R L 13
GCTCTTTGCC TGACGGGCTT AGTGCTCTCG CTCTACGCGC TGCACGTGAA 5400 5’UTR-rev
A L C L T G L V L S L Y A L H V K 30
GGCGGCGCGC GCCCGGGACC GGGATTACCG CGCGCTCTGC GACGTGGGCA 5450
A A R A R D R D Y R A L C D V G 46
CCGCCATCAG CTGTTCGCGC GTCTTCTCCT CCAGGTGTGC ACGGGAGTGG 5500 LC-VKORC1-fw
T A I S C S R V F S S R 58
GAGGCGTGGG GCCTCGGAGC AGGGCGGCCA GGATGCCAGA TGATTATTCT 5550 E1-rev
GGAGTCTGGG ATCGGTGTGC CCGGGGAACG GACACGGGGC TGGACTGCTC 5600
GCGGGGTCGT TGCACAGGGG CTGAGCTACC CAGCGATACT GGTGTTCGAA 5650
ATAAGAGTGC GAGGCAAGGG ACCAGACAGT GCTGGGGACT GGGATTATTC 5700
CGGGGACTCG CACGTGAATT GGATGCCAAG GAATAACGGT GACCAGGAAA 5750
GGCGGGGAGG CAGGATGGCG GTAGAGATTG ACGATGGTCT CAAGGACGGC 5800
GCGCAGGTGA AGGGGGGTGT TGGCGATGGC TGCGCCCAGG AACAAGGTGG 5850 | var(5808):[G:0.18]
CCCGGTCTGG CTGTGCGTGA TGGCCAGGCG TTAGCATAAT GACGGAATAC 5900
AGAGGAGGCG AGTGAGTGGC CAGGGAGCTG GAGATTCTGG GGTCCAGGGC 5950
AAAGATAATC TGCCCCCGAC TCCCAGTCTC TGATGCAAAA CCGAGTGAAC 6000 | var(5970):[A:0.02]
CGTTATACCA GCCTTGCCAT TTTAAGAATT ACTTAAGGGC CGGGCGCGGT 6050 | var(6009):[T:0.14] |
REPEAT
GGCCCACTCC TGTAATCCCA GCACTTTGGG AGGCCGAGGC GGATGGATCA 6100
CTTGAAGTCA GGAGTTGACC AGCCTGGCCA ACATGGTGAA AGCCTGTCTC 6150
TACCAAAAAT AGAAAAATTA ATCGGGCGCT ATGGCGGGTG CCTTAATCCC 6200 | var(6191):[T:0.04]
AGCTACTCGG GGGGGCTAAG GCAGGAGAAT CGCTTGAACC CGGGAGGCGG 6250
AGGTTTCAGT GAGCCGAGAT CGCGCCACTG CACTCCAGCC TGGGCCAGAG 6300
TGAGACTCCG TCTCAAAAAA AAAAAAAAAA AAAAAAAAAA AGAGACTTAC 6350
TTAAGGTCTA AGATGAAAAG CAGGGCCTAC GGAGTAGCCA CGTCCGGGCC 6400
TGGTCTGGGG AGAGGGGAGG ATAGGGTCAG TGACATGGAA TCCTGACGTG 6450 E2-fw
GCCAAAGGTG CCCGGTGCCA GGAGATCATC GACCCTTGGA CTAGGATGGG 6500 | var(6484):[T:0.31]
AGGTCGGGGA ACAGAGGATA GCCCAGGTGG CTTCTTGGAA ATCACCTTTC 6550
TCGGGCAGGG TCCAAGGCAC TGGGTTGACA GTCCTAACCT GGTTCCACCC 6600
CACCCCACCC CTCTGCCAGG TGGGGCAGGG GTTTCGGGCT GGTGGAGCAT 6650 | Exon 2
W G R G F G L V E H 68
GTGCTGGGAC AGGACAGCAT CCTCAATCAA TCCAACAGCA TATTCGGTTG 6700
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V L G Q D S I L N Q S N S I F G C 85
CATCTTCTAC ACACTACAGC TATTGTTAGG TGAGTGGCTC CGCCCCCTCC 6750
I F Y T L Q L L L 94
CTGCCCGCCC CGCCCCGCCC CTCATCCCCC TTGGTCAGCT CAGCCCCACT 6800
CCATGCAATC TTGGTGATCC ACACAGCTGA CAGCCAGCTA GCTGCTCATC 6850 E2-rev
ACGGAGCGTC CTGCGGGTGG GGATGTGGGG AGGTAACTAA CAGGAGTCTT 6900 | var(6853):[C:0.32]
TTAATTGGTT TAAGTACTGT TAGAGGCTGA AGGGCCCTTA AAGACATCCT 6950 | var(6915):[C:0.04]
AGGTCCCCAG GTTTTTTGTT TGTTGTTGTT TTGAGACAGG GTCTGGCTCT 7000 | var(6960):[A:0.01] |
REPEAT
GTTGCCCAAA GTGAGGTCTA GGATGCCCTT AGTGTGCACT GGCGTGATCT 7050
CAGTTCATGG CAACCTCTGC CTCCCTGCCC AAGGGATCCT CCCACCTTAG 7100
CCTCCCAAGC AGCTGGAATC ACAGGCGTGC ACCACTATGC CCAGCTAATT 7150
TTTGTTTTTG TTTTTTTTTG GTAGAGATGG TGTCTCGCCA TGTTGCCCAG 7200
GCTGGTCTCA AGCAATCTGT CTGCCTCAGC CTCCCAAAGT GCTGGGGGGA 7250
TTACAGGCGT GAGCTACCAT GCCCCACCAA CACCCCAGTT TTGTGGAAAA 7300
GATGCCGAAA TTCCTTTTTA AGGAGAAGCT GAGCATGAGC TATCTTTTGT 7350
CTCATTTAGT GCTCAGCAGG AAAATTTGTA TCTAGTCCCA TAAGAACAGA 7400
GAGAGGAACC AAGGGAGTGG AAGACGATGG CGCCCCAGGC CTTGCTGATG 7450
CCATATGCCG GAGATGAGAC TATCCATTAC CACCCTTCCC AGCAGGCTCC 7500
CACGCTCCCT TTGAGTCACC CTTCCCAGCT CCAGAGAAGG CATCACTGAG 7550
GGAGGCCCAG CACCACGGTC CTGGCTGACA CATGGTTCAG ACTTGGCCGA 7600 | var(7566):[T:0.35]
TTTATTTAAG AAATTTTATT GCTCAGAACT TTCCCTCCCT GGGCAATGGC 7650
AAGAGCTTCA GAGACCAGTC CCTTGGAGGG GACCTGTTGA AGCCTTCTTT 7700 | REPEAT
TTTTTTTTTT TTAAGAAATA ATCTTGCTCT GTTGCCCAGG CTGGAGTGCA 7750
GTGGCACAAT CATAGCTCAC TGTAACCTGG CTCAAGCGAT CCTCCTGAGT 7800
AGCTAGGACT ATAGGCATGT CACTGCACCC AGCTAATTTT TTTTTTTTTT 7850 | var(7817):[T:0.01] |
REPEAT
TTTTTTTTTT TTTTGCGACA TAGTCTCGCT CTGTCACCAG GCTGGAGTGC 7900
AGTGGCACGA TCTTGGCTCA CTGCAACCTC TGCCTCCCGG GTTCAAGCAA 7950
TTTTCCTGCC TCAGCCTCCT GAGTAGCTGG GACTACAGGC GCGTGTCACC 8000
ACGCCCAGCT AATTTTTGTA TTTTTAGTGG AGACAGGGTT TCACCATGTT 8050 | var(8026):[G:0.02]
GGCTAGGATG GTCTCAATCT CTTGACCTGG TGATCCATCC GCCTTGGCCT 8100
CCCAAAGTGC TAGGATTACA GGCGTGAGTC AACCTCACCG GGCATTTTTT 8150 | REPEAT | REPEAT
TTTTGAGACG AAGTCTTGCT CTTGCTGCCC AAGCTGGAAT GTGGTGGCAT 8200
GATCTCGGCT CACTGCAACC TCCACCTCCT AGGTTCAAGC GATTCTCCAC 8250
CTTAGCCTCC CCAGCAGCTG GGATTACAGG TGCCCATCAA CACACCCGGC 8300
TAATTTTTGT ATTTTTATTA GAGATGGGGT TTTGCCATGT TGGCCAGGCT 8350
GCTCTCGAAC TCCTAACCTC AGGTGATCCA CCCCCATTGG CCTCCCAAAA 8400
TACTGGGATT ACAGGCATGA GCCACCGTGC CCAGCTGAAT TTCTAAATTT 8450 | REPEAT
TTGATAGAGA TCGGGTCTTT CTATGTTGCC CAAGCTGGTC TTGAACTCCT 8500
AGCCTAAAGC AGTCTTCCCA CCTCGGCCTC CCAGAGTGTT TGGAATACGT 8550
GCGTAAGCCA CCACATCTGC CCTGGAGCCT CTTGTTTTAG AGACCCTTCC 8600
CAGCAGCTCC TGGCATCTAG GTAGTGCAGT GACATCATGG AGTGTTCGGG 8650
AGGTGGCCAG TGCCTGAAGC CCACACCGGA CCCTCTTCTG CCTTGCAGGT 8700 | Exon 3
G 95 E3-fw
TGCCTGCGGA CACGCTGGGC CTCTGTCCTG ATGCTGCTGA GCTCCCTGGT 8750
C L R T R W A S V L M L L S S L V 112
GTCTCTCGCT GGTTCTGTCT ACCTGGCCTG GATCCTGTTC TTCGTGCTCT 8800 | var(8773):[T:0.11]
S L A G S V Y L A W I L F F V L 128 LC-VKORC1-rev
ATGATTTCTG CATTGTTTGT ATCACCACCT ATGCTATCAA CGTGAGCCTG 8850
Y D F C I V C I T T Y A I N V S L 145
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ATGTGGCTCA GTTTCCGGAA GGTCCAAGAA CCCCAGGGCA AGGCTAAGAG 8900
M W L S F R K V Q E P Q G K A K R 162
GCACTGAGCC CTCAACCCAA GCCAGGCTGA CCTCATCTGC TTTGCTTTGG 8950 | UTR
H 163
CATGTGAGCC TTGCCTAAGG GGGCATATCT GGGTCCCTAG AAGGCCCTAG 9000 9041G>A-mut-fw 
9041G>A-wt-fw
ATGTGGGGCT TCTAGATTAC CCCCTCCTCC TGCCATACCC GCACATGACA 9050 | var(9041):[A:0.38]
ATGGACCAAA TGTGCCACAC GCTCGCTCTT TTTTACACCC AGTGCCTCTG 9100
ACTCTGTCCC CATGGGCTGG TCTCCAAAGC TCTTTCCATT GCCCAGGGAG 9150 9041G>A-com-rev
GGAAGGTTCT GAGCAATAAA GTTTCTTAGA TCAATCAGCC AAGTCTGAAC 9200
CATGTGTCTG CCATGGACTG TGGTGCTGGG CCTCCCTCGG TGTTGCCTTC 9250
TCTGGAGCTG GGAAGGGTGA GTCAGAGGGA GAGTGGAGGG CCTGCTGGGA 9300 3’UTR-rev
AGGGTGGTTA TGGGTAGTCT CATCTCCAGT GTGTGGAGTC AGCAAGGCCT 9350
GGGGCACCAT TGGCCCCCAC CCCCAGGAAA CAGGCTGGCA GCTCGCTCCT 9400
GCTGCCCACA GGAGCCAGGC CTCCTCTCCT GGGAAGGCTG AGCACACACC 9450
TGGAAGGGCA GGCTGCCCTT CTGGTTCTGT AAATGCTTGC TGGGAAGTTC 9500
TTCCTTGAGT TTAACTTTAA CCCCTCCAGT TGCCTTATCG ACCATTCCAA 9550
GCCAGTATTG GTAGCCTTGG AGGGTCAGGG CCAGGTTGTG AAGGTTTTTG 9600
TTTTGCCTAT TATGCCCTGA CCACTTACCT ACATGCCAAG CACTGTTTAA 9650 | REPEAT
GAACTTGTGT TGGCAGGGTG CAGTGGCTCA CACCTGTAAT CCCTGTACTT 9700 | REPEAT
TGGGAGGCCA AGGCAGGAGG ATCACTTGAG GCCAGGAGTT CCAGACCAGC 9750 | NOT SCANNED
CTGGGCAAAA TAGTGAGACC CCTGTCTCTA CAAAAAAAAA AAAAAAAAAA 9800
AATTAGCCAG GCATGGTGGT GTATGTACCT ATAGTCCCAA CTAATCGGGA 9850
AGCTGGCGGG AAGACTGCTT GAGCCCAGAA GGTTGAGGCT GCAGTGAGCC 9900
ATGATCACTG CACTCCAGCC TGAGCAACAG AGCAAGACCG TCTCCAAAAA 9950
AAAACAAAAA ACAAAAAAAA ACTTGTGTTA ACGTGTTAAA CTCGTTTAAT 10000 | REPEAT
CTTTACAGTG ATTTATGAGG TGGGTACTAT TATTATCCCT ATCTTGATGA 10050
TAGGGACAGA GTGGCTAATT AGTATGCCTG AGATCACACA GCTACTGCAG 10100
GAGGCTCTCA GGATTTGAAT CCACCTGGTC CATCTGGCTC CAGCATCTAT 10150 | var(10146):[A:0.01]
ATGCTTTTTT TTTTGTTGGT TTGTTTTTGA GACGGACTTT CGCTCTTGTT 10200 | REPEAT
GTCCAGGCTG GAGTGCAATG GCACAATTTC GGCTCACCAC AACCTCCACC 10250 | var(10212):[C:0.05]
TCCCAGGTTC AAGTGATTCT CCTGCCTCAG CCTCCCGAGT AGCTGGGATT 10300
ACAGGCATGC GCCACCAGGC CTGGCTAATT TTGTATTTTT AGTAGAGACA 10350
GTGTTTCTCT ATGTTGGTCA GGCTGGTCTC GCACTCCCGA CCTCAGGTGA 10400
TCTGCCTGCT TTGGCCTCCC AAAGTGCTGG GATTACAGGC GTGAGCCACC 10450 | var(10424):[A:0.05]
ATGCCCGGCC AGCATCTATA ATATATGCTA AACCTTACCC ACAGCTGCCT 10500 | var(10466):[T:0.02]
CTGTCTTGGG GTCAGGGTTC TTGAATGGTC TGGGCCAGCC TGAGTTAGGA 10550
GTGGGAAGAG GAAGAGGAGG CACGCGCCAA AGTGTTCTTC CCGCCTGACC 10600
GAGTCCTCTG CGCCTATGAG GAAGGTGGGC ACCGCTGTCA CCCTGTTTCC 10650 | REPEAT
CAGGAAGCCA GCAGGCCCAG GGAGATACTG GGATTTGCCA AAGGCTCACA 10700
GCGAGCAAGC AGCAGTGGGT GCTGGCTCCT CACCACTCAG CCTGGCACAC 10750 | var(10719):[C:0.05]
ACTGTCTCTG AGCAGACCTG GGAGAAGGCA TGTGAAACCC ACCTAGCCCT 10800
GGCTGGAAGA GAAGTGGGGG AGTGGAAATG AAAAGTGGGG ACTGGGAGGA 10850
GCTGCCCACG TGCCCTCCAT GGTTCCAGGA TGGCACTTTC ATGCTGGGAG 10900
TGAGCTTGCC CTGTGCCAGG CTGTCATTGA GACGTTTTCC ATTCAACAAC 10950
TGTTTCTCAG ACAAGGCACA GGCAGGTTAG CTCTCCCAGG CCACTCAAGT 11000 | REPEAT
AGTAAGGAAA CAGATTTAAA CCCAGACAAT TTGGCTCCAC GGCTAAGGCC 11050 | var(11040):[T:0.01] |
REPEAT
CAGAGAGGGG TGGTGACAAG CCTAGGGTCA CACAGCCACA GCCCCAGAGC 11100
TAGGAACTGC TGGCTAGGGC AAGCAGACAG CTGAATCCTA GCCAACTGGA 11150
GGTGGAGCAG AGGTGGAGCC AGGGAGACCC AGGTGGCCTC
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2. VKORC1 Coding Sequence
1 atgggcagca cctgggggag ccctggctgg gtgcggctcg ctctttgcct 
gacgggctta
61 gtgctctcgc tctacgcgct gcacgtgaag gcggcgcgcg cccgggaccg 
ggattaccgc
121 gcgctctgcg acgtgggcac cgccatcagc tgttcgcgcg tcttctcctc 
caggtggggc
181 aggggtttcg ggctggtgga gcatgtgctg ggacaggaca gcatcctcaa 
tcaatccaac
241 agcatattcg gttgcatctt ctacacacta cagctattgt taggttgcct 
gcggacacgc
301 tgggcctctg tcctgatgct gctgagctcc ctggtgtctc tcgctggttc 
tgtctacctg
361 gcctggatcc tgttcttcgt gctctatgat ttctgcattg tttgtatcac 
cacctatgct
421 atcaacgtga gcctgatgtg gctcagtttc cggaaggtcc aagaacccca 
gggcaaggct
481 aagaggcact ga
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